



**FOSFODIESTERASAS DEL AMP<sub>c</sub> Y DEL GMP<sub>c</sub> EN EL  
CEREBRO: EXPRESIÓN EN PROCESOS  
NEUROINFLAMATORIOS Y NEURODEGENERATIVOS**

Elisabet Reyes Irisarri  
Barcelona 2007

## ***Bibliografía***



- 't Hart BA, Amor S, and Jonker M. 2004. Evaluating the validity of animal models for research into therapies for immune-based disorders. *Drug Discovery Today* 9:517-524.
- Abbott NJ and Romero IA. 1996. Transporting therapeutics across the blood-brain barrier. *Mol Med Today* 2:106-113.
- Abdel-Latif AA. 2001. Cross talk between cyclic nucleotides and polyphosphoinositide hydrolysis, protein kinases, and contraction in smooth muscle. *Exp Biol Med* 226:153-163.
- Abrahamsen H, Baillie G, Ngai J, Vang T, Nika K, Ruppelt A, Mustelin T, Zaccolo M, Houslay M, and Tasken K. 2004. TCR- and CD28-mediated recruitment of phosphodiesterase 4 to lipid rafts potentiates TCR signaling. *J Immunol* 173:4847-4858.
- Adachi H, Kakiki M, and Kishi Y. 2005. Effects of a phosphodiesterase 3 inhibitor, olprinone, on rhythmical change in tension of human gastroepiploic artery. *Eur J Pharmacol* 528:137-143.
- Ahmed T and Frey JU. 2003. Expression of the specific type IV phosphodiesterase gene PDE4B3 during different phases of long-term potentiation in single hippocampal slices of rats in vitro. *Neuroscience* 117:627-638.
- Airaksinen E, Larsson M, Lundberg I, and Forsell Y. 2004. Cognitive functions in depressive disorders: evidence from a population-based study. *Psychol Med* 34:83-91.
- Aisen PS, Marin D, Altstiel L, Goodwin C, Baruch B, Jacobson R, Ryan T, and Davis KL. 1996. A pilot study of prednisone in Alzheimer's disease. *Dementia* 7:201-206.
- Akasaka S, Nomura M, Nishii H, Fujimoto N, Ueta Y, Tsutsui M, Shimokawa H, Yanagihara N, and Matsumoto T. 2006. The hypothalamo-pituitary axis responses to lipopolysaccharide-induced endotoxemia in mice lacking inducible nitric oxide synthase. *Brain Res* 1089:1-9.
- Akwa Y, Hassett DE, Eloranta ML, Sandberg K, Masliah E, Powell H, Whitton JL, Bloom FE, and Campbell IL. 1998. Transgenic expression of IFN-alpha in the central nervous system of mice protects against lethal neurotropic viral infection but induces inflammation and neurodegeneration. *J Immunol* 161:5016-5026.
- Albert PR, Sajedi N, Lemonde S, and Ghahremani MH. 1999. Constitutive G(i2)-dependent activation of adenylyl cyclase type II by the 5-HT1A receptor. Inhibition by anxiolytic partial agonists. *J Biol Chem* 274:35469-35474.
- Alexander SPH, Mathie A, and Peters JA. 2004. Guide to receptors and channels, 1st edition. *British Journal of Pharmacology* 141:S1-S126.
- Altmann DM and Boyton RJ. 2004. Models of multiple sclerosis. *Drug Discovery Today* 1:405-410.
- Alvarez R, Sette C, Yang D, Eglén RM, Wilhelm R, Shelton ER, and Conti M. 1995. Activation and selective inhibition of a cyclic AMP-specific phosphodiesterase, PDE-4D3. *Mol Pharmacol* 48:616-622.
- Andersson PB, Perry VH, and Gordon S. 1992. The acute inflammatory response to lipopolysaccharide in CNS parenchyma differs from that in other body tissues. *Neuroscience* 48:169-186.
- Andjelkovic AV, Nikolic B, Pachter JS, and Zecevic N. 1998. Macrophages/microglial cells in human central nervous system during development: an immunohistochemical study. *Brain Res* 814:13-25.
- Andoh T, Chock PB, and Chiueh CC. 2002. Preconditioning-mediated neuroprotection: role of nitric oxide, cGMP, and new protein expression. *Ann N Y Acad Sci* 962:1-7.
- Andreeva SG, Dikkes P, Epstein PM, and Rosenberg PA. 2001. Expression of cGMP-specific phosphodiesterase 9A mRNA in the rat brain. *J Neurosci* 21:9068-9076.
- Angelov DN, Walther M, Streppel M, Guntinas-Lichius O, and Neiss WF. 1998. The cerebral perivascular cells. *Adv Anat Embryol Cell Biol* 147:1-87.
- Archelos JJ, Jung S, Maurer M, Schmieid M, Lassmann H, Tamatani T, Miyasaka M, Toyka KV, and Hartung HP. 1993. Inhibition of experimental autoimmune encephalomyelitis by an antibody to the intercellular adhesion molecule ICAM-1. *Ann Neurol* 34:145-154.
- Ariga M, Neitzert B, Nakae S, Mottin G, Bertrand C, Pruniaux MP, Jin SL, and Conti M. 2004. Nonredundant function of phosphodiesterases 4D and 4B in neutrophil recruitment to the site of inflammation. *J Immunol* 173:7531-7538.
- Arp J, Kirchhof MG, Baroja ML, Nazarian SH, Chau TA, Strathdee CA, Ball EH, and Madrenas J. 2003. Regulation of T-cell activation by phosphodiesterase 4B2 requires its dynamic redistribution during immunological synapse formation. *Mol Cell Biol* 23:8042-8057.
- ASHMAN DF, PRICE TD, MELICOW MM, and LIPTON R. 1963. Isolation of Adenosine 3,5-Monophosphate and Guanosine 3,5-Monophosphate from Rat Urine. *Biochemical and Biophysical Research Communications* 11:330-&.
- Asirvatham AL, Galligan SG, Schillace RV, Davey MP, Vasta V, Beavo JA, and Carr DW. 2004. A-kinase anchoring proteins interact with phosphodiesterases in T lymphocyte cell lines. *J Immunol* 173:4806-4814.
- Bach ME, Barad M, Son H, Zhuo M, Lu YF, Shih R, Mansuy I, Hawkins RD, and Kandel ER. 1999. Age-related defects in spatial memory are correlated with defects in the late phase of hippocampal long-term potentiation in vitro and are attenuated by drugs that enhance the cAMP signaling pathway. *Proc Natl Acad Sci U S A* 96:5280-5285.
- Baecker PA, Obernolte R, Bach C, Yee C, and Shelton ER. 1994. Isolation of a cDNA encoding a human rolipram-sensitive cyclic AMP phosphodiesterase (PDE IVD). *Gene* 138:253-256.
- Baillie GS and Houslay MD. 2005. Arrestin times for compartmentalised cAMP signalling and

- phosphodiesterase-4 enzymes. *Curr Opin Cell Biol* 17:129-134.
- Baillie GS, Huston E, Scotland G, Hodgkin M, Gall I, Peden AH, MacKenzie C, Houslay ES, Currie R, Pettitt TR, Walmsley AR, Wakelam MJ, Warwicker J, and Houslay MD. 2002. TAPAS-1, a novel microdomain within the unique N-terminal region of the PDE4A1 cAMP-specific phosphodiesterase that allows rapid, Ca<sup>2+</sup>-triggered membrane association with selectivity for interaction with phosphatidic acid. *J Biol Chem* 277:28298-28309.
- Baillie GS, MacKenzie SJ, McPhee I, and Houslay MD. 2000. Sub-family selective actions in the ability of Erk2 MAP kinase to phosphorylate and regulate the activity of PDE4 cyclic AMP-specific phosphodiesterases. *Br J Pharmacol* 131:811-819.
- Baillie GS, Scott JD, and Houslay MD. 2005. Compartmentalisation of phosphodiesterases and protein kinase A: opposites attract. *FEBS Lett* 579:3264-3270.
- Bajetto A, Bonavia R, Barbero S, Florio T, and Schettini G. 2001. Chemokines and their receptors in the central nervous system. *Front Neuroendocrinol* 22:147-184.
- Bajetto A, Bonavia R, Barbero S, and Schettini G. 2002. Characterization of chemokines and their receptors in the central nervous system: physiopathological implications. *J Neurochem* 82:1311-1329.
- Bal-Price A and Brown GC. 2001. Inflammatory neurodegeneration mediated by nitric oxide from activated glia-inhibiting neuronal respiration, causing glutamate release and excitotoxicity. *J Neurosci* 21:6480-6491.
- Ballerini P, Di Iorio P, Ciccarelli R, Nargi E, D'Alimonte I, Traversa U, Rathbone MP, and Caciagli F. 2002. Glial cells express multiple ATP binding cassette proteins which are involved in ATP release. *Neuroreport* 13:1789-1792.
- Baltrons MA, Pifarre P, Ferrer I, Carot JM, and Garcia A. 2004. Reduced expression of NO-sensitive guanylyl cyclase in reactive astrocytes of Alzheimer disease, Creutzfeldt-Jakob disease, and multiple sclerosis brains. *Neurobiol Dis* 17:462-472.
- Barad M, Bourtchouladze R, Winder DG, Golan H, and Kandel E. 1998. Rolipram, a type IV-specific phosphodiesterase inhibitor, facilitates the establishment of long-lasting long-term potentiation and improves memory. *Proc Natl Acad Sci U S A* 95:15020-15025.
- Baranano DE, Ferris CD, and Snyder SH. 2001. Atypical neural messengers. *Trends Neurosci* 24:99-106.
- Barnes AP, Livera G, Huang P, Sun C, O'Neal WK, Conti M, Stutts MJ, and Milgram SL. 2005. Phosphodiesterase 4D forms a cAMP diffusion barrier at the apical membrane of the airway epithelium. *J Biol Chem* 280:7997-8003.
- Barnes MJ, Cooper N, Davenport RJ, Dyke HJ, Galleway FP, Galvin FC, Gowers L, Haughan AF, Lowe C, Meissner JW, Montana JG, Morgan T, Picken CL, and Watson RJ. 2001. Synthesis and structure-activity relationships of guanine analogues as phosphodiesterase 7 (PDE7) inhibitors. *Bioorg Med Chem Lett* 11:1081-1083.
- Baroja ML, Cieslinski LB, Torphy TJ, Wange RL, and Madrenas J. 1999. Specific CD3 epsilon association of a phosphodiesterase 4B isoform determines its selective tyrosine phosphorylation after CD3 ligation. *J Immunol* 162:2016-2023.
- Basu A, Krady JK, and Levison SW. 2004. Interleukin-1: a master regulator of neuroinflammation. *J Neurosci Res* 78:151-156.
- Baumer W, Hoppmann J, Rundfeldt C, and Kietzmann M. 2007. Highly selective phosphodiesterase 4 inhibitors for the treatment of allergic skin diseases and psoriasis. *Inflamm Allergy Drug Targets* 6:17-26.
- Bazan NG, Colangelo V, and Lukiw WJ. 2002. Prostaglandins and other lipid mediators in Alzheimer's disease. *Prostaglandins Other Lipid Mediat* 68-69:197-210.
- Beard MB, O'Connell JC, Bolger GB, and Houslay MD. 1999. The unique N-terminal domain of the cAMP phosphodiesterase PDE4D4 allows for interaction with specific SH3 domains. *FEBS Lett* 460:173-177.
- Beard MB, Olsen AE, Jones RE, Erdogan S, Houslay MD, and Bolger GB. 2000. UCR1 and UCR2 domains unique to the cAMP-specific phosphodiesterase family form a discrete module via electrostatic interactions. *J Biol Chem* 275:10349-10358.
- Beavo JA. 1995a. cGMP inhibition of heart phosphodiesterase: is it clinically relevant? [editorial; comment]. *J Clin Invest* 95:445.
- Beavo JA. 1995b. Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. *Physiol Rev* 75:725-748.
- Beavo JA and Brunton LL. 2002. Cyclic nucleotide research -- still expanding after half a century. *Nat Rev Mol Cell Biol* 3:710-718.
- Beavo JA, Conti M, and Heasley RJ. 1994. Multiple cyclic nucleotide phosphodiesterases. *Mol Pharmacol* 46:399-405.
- Beavo JA, Hardman JG, and Sutherland EW. 1971. Stimulation of adenosine 3',5'-monophosphate hydrolysis by guanosine 3',5'-monophosphate. *J Biol Chem* 246:3841-3846.
- Beavo JA and Reifsnnyder DH. 1990. Primary sequence of cyclic nucleotide phosphodiesterase isozymes and the design of selective inhibitors. *Trends Pharmacol Sci* 11:150-155.
- Behn D and Potter MJ. 2001. Sildenafil-mediated reduction in retinal function in heterozygous mice lacking the gamma-subunit of phosphodiesterase. *Invest Ophthalmol Vis Sci* 42:523-527.
- Bender AT and Beavo JA. 2006. Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. *Pharmacol Rev* 58:488-520.

- Berrendero F, Sanchez A, Cabranes A, Puerta C, Ramos JA, Garcia-Merino A, and Fernandez-Ruiz J. 2001. Changes in cannabinoid CB(1) receptors in striatal and cortical regions of rats with experimental allergic encephalomyelitis, an animal model of multiple sclerosis. *Synapse* 41:195-202.
- BERTHET J, RALL TW, and Sutherland EW. 1957. The relationship of epinephrine and glucagon to liver phosphorylase. IV. Effect of epinephrine and glucagon on the reactivation of phosphorylase in liver homogenates. *J Biol Chem* 224:463-475.
- Bertolino A, Crippa D, di Dio S, Fichte K, Musmeci G, Porro V, Rapisarda V, Sastre, and Schratzer M. 1988. Risperidone versus imipramine in inpatients with major, "minor" or atypical depressive disorder: a double-blind double-dummy study aimed at testing a novel therapeutic approach. *Int Clin Psychopharmacol* 3:245-253.
- Biber K, Sauter A, Brouwer N, Copray SC, and Boddeke HW. 2001. Ischemia-induced neuronal expression of the microglia attracting chemokine Secondary Lymphoid-tissue Chemokine (SLC). *Glia* 34:121-133.
- Bielekova B, Lincoln A, McFarland H, and Martin R. 2000. Therapeutic potential of phosphodiesterase-4 and -3 inhibitors in Th1-mediated autoimmune diseases. *J Immunol* 164:1117-1124.
- Bigazzi PE. 1995. Animal models of multiple sclerosis. *Clin Immunol Immunopathol* 77:3.
- Blease K, Burke-Gaffney A, and Hellewell PG. 1998. Modulation of cell adhesion molecule expression and function on human lung microvascular endothelial cells by inhibition of phosphodiesterases 3 and 4. *Br J Pharmacol* 124:229-237.
- Bliss TV and Gardner-Medwin AR. 1973. Long-lasting potentiation of synaptic transmission in the dentate area of the unanaesthetized rabbit following stimulation of the perforant path. *J Physiol* 232:357-374.
- Bliss TV and Lomo T. 1973. Long-lasting potentiation of synaptic transmission in the dentate area of the anaesthetized rabbit following stimulation of the perforant path. *J Physiol* 232:331-356.
- Blokland A, Schreiber R, and Prickaerts J. 2006. Improving memory: a role for phosphodiesterases. *Curr Pharm Des* 12:2511-2523.
- Bloom TJ and Beavo JA. 1996. Identification and tissue-specific expression of PDE7 phosphodiesterase splice variants. *Proc Natl Acad Sci U S A* 93:14188-14192.
- Blumer KJ and Johnson GL. 1994. Diversity in function and regulation of MAP kinase pathways. *Trends Biochem Sci* 19:236-240.
- Blusztajn JK and Berse B. 2000. The cholinergic neuronal phenotype in Alzheimer's disease. *Metab Brain Dis* 15:45-64.
- Bobon D, Breulet M, Gerard-Vandenhove MA, Guiot-Goffioul F, Plomteux G, Sastre, Schratzer M, Troisfontaines B, von Frenckell R, and Wachtel H. 1988. Is phosphodiesterase inhibition a new mechanism of antidepressant action? A double blind double-dummy study between risperidone and desipramine in hospitalized major and/or endogenous depressives. *Eur Arch Psychiatry Neurol Sci* 238:2-6.
- Boess FG, Hendrix M, van der Staay FJ, Erb C, Schreiber R, van Staveren W, de Vente J, Prickaerts J, Blokland A, and Koenig G. 2004. Inhibition of phosphodiesterase 2 increases neuronal cGMP, synaptic plasticity and memory performance. *Neuropharmacology* 47:1081-1092.
- Boguski MS and McCormick F. 1993. Proteins regulating Ras and its relatives. *Nature* 366:643-654.
- Bolger G, Michaeli T, Martins T, St. John T, Steiner B, Rodgers L, Riggs M, Wigler M, and Ferguson K. 1993. A family of human phosphodiesterases homologous to the dunce learning and memory gene product of *Drosophila melanogaster* are potential targets for antidepressant drugs. *Mol Cell Biol* 13:6558-6571.
- Bolger GB, Erdogan S, Jones RE, Loughney K, Scotland G, Hoffmann R, Wilkinson I, Farrell C, and Houslay MD. 1997. Characterization of five different proteins produced by alternatively spliced mRNAs from the human cAMP-specific phosphodiesterase PDE4D gene. *Biochem J* 328 ( Pt 2):539-548.
- Bolger GB, McCahill A, Huston E, Cheung YF, McSorley T, Baillie GS, and Houslay MD. 2003. The unique amino-terminal region of the PDE4D5 cAMP phosphodiesterase isoform confers preferential interaction with beta-arrestins. *J Biol Chem* 278:49230-49238.
- Bolger GB, Rodgers L, and Riggs M. 1994. Differential CNS expression of alternative mRNA isoforms of the mammalian genes encoding cAMP-specific phosphodiesterases. *Gene* 149:237-244.
- Bonkale WL, Cowburn RF, Ohm TG, Bogdanovic N, and Fastbom J. 1999. A quantitative autoradiographic study of [<sup>3</sup>H]cAMP binding to cytosolic and particulate protein kinase A in post-mortem brain staged for Alzheimer's disease neurofibrillary changes and amyloid deposits. *Brain Res* 818:383-396.
- Bonkale WL, Winblad B, Ravid R, and Cowburn RF. 1995. Reduced nitric oxide responsive soluble guanylyl cyclase activity in the superior temporal cortex of patients with Alzheimer's disease. *Neurosci Lett* 187:5-8.
- Boolell M, Allen MJ, Ballard SA, Gepi-Attee S, Muirhead GJ, Naylor AM, Osterloh IH, and Gingell C. 1996. Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. *Int J Impot Res* 8:47-52.
- Borinson H.L. and Wang SC. 1953. Physiology and pharmacology of vomiting. *Pharmacol Rev* 5:193-230.
- Borrelli E, Montmayeur JP, Foulkes NS, and Sassone-Corsi P. 1992. Signal transduction

## Bibliografía

- and gene control: the cAMP pathway. *Crit Rev Oncog* 3:321-338.
- Borst P and Elferink RO. 2002. Mammalian ABC transporters in health and disease. *Annual Review of Biochemistry* 71:537-592.
- Bouron A and Reuter H. 1999. The D1 dopamine receptor agonist SKF-38393 stimulates the release of glutamate in the hippocampus. *Neuroscience* 94:1063-1070.
- Braak H and Braak E. 1991. Neuropathological staging of Alzheimer-related changes. *Acta Neuropathol (Berl)* 82:239-259.
- Braak H and Braak E. 1997. Frequency of stages of Alzheimer-related lesions in different age categories. *Neurobiol Aging* 18:351-357.
- Braak H, Braak E, Bohl J, and Bratzke H. 1998. Evolution of Alzheimer's disease related cortical lesions. *J Neural Transm Suppl* 54:97-106.
- Bradley J, Zhang YN, Bakin R, Lester HA, Ronnett GV, and Zinn K. 1997. Functional expression of the heteromeric "olfactory" cyclic nucleotide-gated channel in the hippocampus: A potential effector of synaptic plasticity in brain neurons. *Journal of Neuroscience* 17:1993-2005.
- Brandon EP, Idzerda RL, and McKnight GS. 1997. PKA isoforms, neural pathways, and behaviour: making the connection. *Curr Opin Neurobiol* 7:397-403.
- Braun T and Dods RF. 1975. Development of a Mn<sup>2+</sup>-Sensitive, Soluble Adenylate Cyclase in Rat Testis. *Proceedings of the National Academy of Sciences of the United States of America* 72:1097-1101.
- Breder CD, Hazuka C, Ghayur T, Klug C, Huginin M, Yasuda K, Teng M, and Saper CB. 1994. Regional induction of tumor necrosis factor alpha expression in the mouse brain after systemic lipopolysaccharide administration. *Proc Natl Acad Sci U S A* 91:11393-11397.
- Bredt DS and Snyder SH. 1989. Nitric oxide mediates glutamate-linked enhancement of cGMP levels in the cerebellum. *Proc Natl Acad Sci U S A* 86:9030-9033.
- Brenner S, Prosch S, Schenke-Layland K, Riese U, Gausmann U, and Platzer C. 2003. cAMP-induced Interleukin-10 promoter activation depends on CCAAT/enhancer-binding protein expression and monocytic differentiation. *J Biol Chem* 278:5597-5604.
- Broadwell RD and Salzman M. 1981. Expanding the definition of the blood-brain barrier to protein. *Proc Natl Acad Sci U S A* 78:7820-7824.
- Brown TH, Chapman PF, Kairiss EW, and Keenan CL. 1988. Long-term synaptic potentiation. *Science* 242:724-728.
- Brown TH and Zador AM. 1990. Hippocampus. In Gordon M. Shepherd, editor. *The Synaptic Organization of the Brain*. New York: Oxford University Press. p 346-388.
- Burgunder JM and Cheung PT. 1994. Expression of Soluble Guanylyl Cyclase Gene in Adult-Rat Brain. *European Journal of Neuroscience* 6:211-217.
- Burns F, Zhao AZ, and Beavo JA. 1996. Cyclic nucleotide phosphodiesterases: gene complexity, regulation by phosphorylation, and physiological implications. *Adv Pharmacol* 36:29-48.
- Butcher RW and Sutherland EW. 1962. Adenosine 3',5'-Phosphate in Biological Materials. *J Biol Chem* 237:1244-1250.
- Byers D, Davis RL, and Kiger JAJ. 1981. Defect in cyclic AMP phosphodiesterase due to the dunce mutation of learning in *Drosophila melanogaster*. *Nature* 289:79-81.
- Cali JJ, Parekh RS, and Krupinski J. 1996. Splice variants of type VIII adenylyl cyclase. Differences in glycosylation and regulation by Ca<sup>2+</sup>/calmodulin. *J Biol Chem* 271:1089-1095.
- Campbell IL. 2005. Cytokine-mediated inflammation, tumorigenesis, and disease-associated JAK/STAT/SOCS signaling circuits in the CNS. *Brain Res Brain Res Rev* 48:166-177.
- Campbell IL and Powell HC. 1996. Role of Cytokines in Demyelinating Disease Studied in Transgenic Mice. *Methods* 10:462-477.
- Cannella B, Cross AH, and Raine CS. 1991. Adhesion-related molecules in the central nervous system. Upregulation correlates with inflammatory cell influx during relapsing experimental autoimmune encephalomyelitis. *Lab Invest* 65:23-31.
- Cano E and Mahadevan LC. 1995. Parallel signal processing among mammalian MAPKs. *Trends Biochem Sci* 20:117-122.
- Cao C, Matsumura K, Yamagata K, and Watanabe Y. 1997. Involvement of cyclooxygenase-2 in LPS-induced fever and regulation of its mRNA by LPS in the rat brain. *Am J Physiol* 272:R1712-R1725.
- Card GL, Blasdel L, England BP, Zhang C, Suzuki Y, Gillette S, Fong D, Ibrahim PN, Artis DR, Bollag G, Milburn MV, Kim SH, Schlessinger J, and Zhang KY. 2005. A family of phosphodiesterase inhibitors discovered by cocrystallography and scaffold-based drug design. *Nat Biotechnol* 23:201-207.
- Carpenter DO, Briggs DB, Knox AP, and Strominger N. 1988. Excitation of area postrema neurons by transmitters, peptides, and cyclic nucleotides. *J Neurophysiol* 59:358-369.
- Carson MJ. 2002. Microglia as liaisons between the immune and central nervous systems: functional implications for multiple sclerosis. *Glia* 40:218-231.
- Carson MJ, Reilly CR, Sutcliffe JG, and Lo D. 1998. Mature microglia resemble immature antigen-presenting cells. *Glia* 22:72-85.
- Castro A, Abasolo MI, Gil C, Segarra V, and Martínez A. 2001. CoMFA of benzyl derivatives of 2,1,3-benzo and benzothieno[3,2- $\alpha$ ]thiadiazine 2,2-dioxides: clues for the design of phosphodiesterase 7 inhibitors. *Eur J Med Chem* 36:333-338.
- Castro A, Jerez MJ, Gil C, and Martínez A. 2005. Cyclic nucleotide phosphodiesterases and

- their role in immunomodulatory responses: advances in the development of specific phosphodiesterase inhibitors. *Med Res Rev* 25:229-244.
- Cellerino A, Bahr M, and Isenmann S. 2000. Apoptosis in the developing visual system. *Cell and Tissue Research* 301:53-69.
- Chang BY, Conroy KB, Machleder EM, and Cartwright CA. 1998. RACK1, a receptor for activated C kinase and a homolog of the beta subunit of G proteins, inhibits activity of src tyrosine kinases and growth of NIH 3T3 cells. *Mol Cell Biol* 18:3245-3256.
- Chang BY, Harte RA, and Cartwright CA. 2002. RACK1: a novel substrate for the Src protein-tyrosine kinase. *Oncogene* 21:7619-7629.
- Charbonneau H, Prusti RK, LeTrong H, Sonnenburg WK, Mullaney PJ, Walsh KA, and Beavo JA. 1990. Identification of a noncatalytic cGMP-binding domain conserved in both the cGMP-stimulated and photoreceptor cyclic nucleotide phosphodiesterases. *Proc Natl Acad Sci U S A* 87:288-292.
- Chelmickaschorr E, Kwasniewski MN, Thomas BE, and Arnason BGW. 1989. The Beta-Adrenergic Agonist Isoproterenol Suppresses Experimental Allergic Encephalomyelitis in Lewis Rats. *Journal of Neuroimmunology* 25:203-207.
- Chen C and Regehr WG. 1997. The mechanism of cAMP-mediated enhancement at a cerebellar synapse. *J Neurosci* 17:8687-8694.
- Chen HW, Jiang WS, and Tzeng CR. 2001a. Nitric oxide as a regulator in preimplantation embryo development and apoptosis. *Fertility and Sterility* 75:1163-1171.
- Chen S, Dell EJ, Lin F, Sai J, and Hamm HE. 2004. RACK1 regulates specific functions of Gbetagamma. *J Biol Chem* 279:17861-17868.
- Chen S, Lin F, and Hamm HE. 2005. RACK1 binds to a signal transfer region of G betagamma and inhibits phospholipase C beta2 activation. *J Biol Chem* 280:33445-33452.
- Chen Z, Nield HS, Sun H, Barbier A, and Patel TB. 1995. Expression of type V adenylyl cyclase is required for epidermal growth factor-mediated stimulation of cAMP accumulation. *J Biol Chem* 270:27525-27530.
- Chen ZS, Lee K, and Kruh GD. 2001b. Transport of cyclic nucleotides and estradiol 17-beta-D-glucuronide by multidrug resistance protein 4 - Resistance to 6-mercaptopurine and 6-thioguanine. *Journal of Biological Chemistry* 276:33747-33754.
- Cheng JF and Grande JP. 2007. Cyclic nucleotide phosphodiesterase (PDE) inhibitors: Novel therapeutic agents for progressive renal disease. *Experimental Biology and Medicine* 232:38-51.
- Cherfils J and Chardin P. 1999. GEFs: structural basis for their activation of small GTP-binding proteins. *Trends Biochem Sci* 24:306-311.
- Cherry JA and Davis RL. 1999. Cyclic AMP phosphodiesterases are localized in regions of the mouse brain associated with reinforcement, movement, and affect. *J Comp Neurol* 407:287-301.
- Chiang CS, Powell HC, Gold LH, Samimi A, and Campbell IL. 1996. Macrophage/microglial-mediated primary demyelination and motor disease induced by the central nervous system production of interleukin-3 in transgenic mice. *J Clin Invest* 97:1512-1524.
- Choi YH, Ekholm D, Krall J, Ahmad F, Degerman E, Manganiello VC, and Movsesian MA. 2001. Identification of a novel isoform of the cyclic-nucleotide phosphodiesterase PDE3A expressed in vascular smooth-muscle myocytes. *Biochem J* 353:41-50.
- Ciani E, Guidi S, Bartesaghi R, and Contestabile A. 2002. Nitric oxide regulates cGMP-dependent cAMP-responsive element binding protein phosphorylation and Bcl-2 expression in cerebellar neurons: implication for a survival role of nitric oxide. *J Neurochem* 82:1282-1289.
- Cirillo MA and Seidman LJ. 2003. Verbal declarative memory dysfunction in schizophrenia: from clinical assessment to genetics and brain mechanisms. *Neuropsychol Rev* 13:43-77.
- Coimbra R, Melbostad H, Loomis W, Tobar M, and Hoyt DB. 2005a. Phosphodiesterase inhibition decreases nuclear factor-kappaB activation and shifts the cytokine response toward anti-inflammatory activity in acute endotoxemia. *J Trauma* 59:575-582.
- Coimbra R, Porcides RD, Melbostad H, Loomis W, Tobar M, Hoyt DB, and Wolf P. 2005b. Nonspecific phosphodiesterase inhibition attenuates liver injury in acute endotoxemia. *Surg Infect (Larchmt)* 6:73-85.
- Comery TA, Martone RL, Aschmies S, Atchison KP, Diamantidis G, Gong X, Zhou H, Kreft AF, Pangalos MN, Sonnenberg-Reines J, Jacobsen JS, and Marquis KL. 2005. Acute gamma-secretase inhibition improves contextual fear conditioning in the Tg2576 mouse model of Alzheimer's disease. *J Neurosci* 25:8898-8902.
- Consilvio C, Vincent AM, and Feldman EL. 2004. Neuroinflammation, COX-2, and ALS--a dual role? *Exp Neurol* 187:1-10.
- Conti M. 2000. Phosphodiesterases and cyclic nucleotide signaling in endocrine cells. *Mol Endocrinol* 14:1317-1327.
- Conti M and Jin SL. 1999. The molecular biology of cyclic nucleotide phosphodiesterases. *Prog Nucleic Acid Res Mol Biol* 63:1-38.
- Conti M, Nemoz G, Sette C, and Vicini E. 1995. Recent progress in understanding the hormonal regulation of phosphodiesterases. *Endocr Rev* 16:370-389.
- Conti M, Richter W, Mehats C, Livera G, Park JY, and Jin C. 2003. Cyclic AMP-specific PDE4 phosphodiesterases as critical components of cyclic AMP signaling. *J Biol Chem* 278:5493-5496.
- Cook TA, Ghomashchi F, Gelb MH, Florio SK, and Beavo JA. 2000. Binding of the delta subunit to rod phosphodiesterase catalytic subunits



- requires methylated, prenylated C-termini of the catalytic subunits. *Biochemistry* 39:13516-13523.
- Cook TA, Ghomashchi F, Gelb MH, Florio SK, and Beavo JA. 2001. The delta subunit of type 6 phosphodiesterase reduces light-induced cGMP hydrolysis in rod outer segments. *J Biol Chem* 276:5248-5255.
- Cooper DM, Mons N, and Karpen JW. 1995. Adenylyl cyclases and the interaction between calcium and cAMP signalling. *Nature* 374:421-424.
- Coquil JF, Franks DJ, Wells JN, Dupuis M, and Hamet P. 1980. Characteristics of a new binding protein distinct from the kinase for guanosine 3':5'-monophosphate in rat platelets. *Biochim Biophys Acta* 631:148-165.
- Corbin JD. 2004. Mechanisms of action of PDE5 inhibition in erectile dysfunction. *Int J Impot Res* 16 Suppl 1:S4-S7.
- Corbin JD and Francis SH. 1999. Cyclic GMP phosphodiesterase-5: target of sildenafil. *J Biol Chem* 274:13729-13732.
- Corbin JD, Ogreid D, Miller JP, Suva RH, Jastorff B, and Doskeland SO. 1986. Studies of Cgmp Analog Specificity and Function of the 2 Intrasubunit Binding-Sites of Cgmp-Dependent Protein-Kinase. *Journal of Biological Chemistry* 261:1208-1214.
- Corbin JD, Thomas MK, Wolfe L, Shabb JB, Woodford TA, and Francis SH. 1990. New Insights Into Cgmp Action. *Advances in Second Messenger and Phosphoprotein Research* 24:411-418.
- Corbin JD, Turko IV, Beasley A, and Francis SH. 2000. Phosphorylation of phosphodiesterase-5 by cyclic nucleotide-dependent protein kinase alters its catalytic and allosteric cGMP-binding activities. *Eur J Biochem* 267:2760-2767.
- Correale J and Villa A. 2004. The neuroprotective role of inflammation in nervous system injuries. *J Neurol* 251:1304-1316.
- Cortés R, Mengod G, Celada P, and Artigas F. 1993. p-chlorophenylalanine increases tryptophan-5-hydroxylase mRNA levels in the rat dorsal raphe: a time course study using in situ hybridization. *J Neurochem* 60:761-764.
- Coskran TM, Morton D, Menniti FS, Adamowicz WO, Kleiman RJ, Ryan AM, Strick CA, Schmidt CJ, and Stephenson DT. 2006. Immunohistochemical Localization of Phosphodiesterase 10A (PDE10A) in Multiple Mammalian Species. *J Histochem Cytochem*.
- Cowburn RF, Fowler CJ, and O'Neill C. 1996. Neurotransmitters, signal transduction and second-messengers in Alzheimer's disease. *Acta Neurol Scand Suppl* 165:25-32.
- Crespo P, Xu N, Simonds WF, and Gutkind JS. 1994. Ras-dependent activation of MAP kinase pathway mediated by G-protein beta gamma subunits. *Nature* 369:418-420.
- Cserr HF and Knopf PM. 1992. Cervical lymphatics, the blood-brain barrier and the immunoreactivity of the brain: a new view. *Immunol Today* 13:507-512.
- Cummings JL, Donohue JA, and Brooks RL. 2000. The relationship between donepezil and behavioral disturbances in patients with Alzheimer's disease. *Am J Geriatr Psychiatry* 8:134-140.
- Cummings JL, Vinters HV, Cole GM, and Khachaturian ZS. 1998. Alzheimer's disease: etiologies, pathophysiology, cognitive reserve, and treatment opportunities. *Neurology* 51:S2-17.
- D'Amours MR, Granovsky AE, Artemyev NO, and Cote RH. 1999. Potency and mechanism of action of E4021, a type 5 phosphodiesterase isozyme-selective inhibitor, on the photoreceptor phosphodiesterase depend on the state of activation of the enzyme. *Mol Pharmacol* 55:508-514.
- D'Andrea MR, Qiu Y, Haynes-Johnson D, Bhattacharjee S, Kraft P, and Lundeen S. 2005. Expression of PDE11A in normal and malignant human tissues. *J Histochem Cytochem* 53:895-903.
- D'Sa C, Tolbert LM, Conti M, and Duman RS. 2002. Regulation of cAMP-specific phosphodiesterases type 4B and 4D (PDE4) splice variants by cAMP signaling in primary cortical neurons. *J Neurochem* 81:745-757.
- Dal Canto MC, Melvold RW, Kim BS, and Miller SD. 1995. Two models of multiple sclerosis: experimental allergic encephalomyelitis (EAE) and Theiler's murine encephalomyelitis virus (TMEV) infection. A pathological and immunological comparison. *Microsc Res Tech* 32:215-229.
- Dauwalder B and Davis RL. 1995. Conditional rescue of the dunce learning/memory and female fertility defects with *Drosophila* or rat transgenes. *J Neurosci* 15:3490-3499.
- Davis RL. 1996. Physiology and biochemistry of *Drosophila* learning mutants. *Physiol Rev* 76:299-317.
- Davis RL, Cherry J, Dauwalder B, Han PL, and Skoulakis E. 1995. The cyclic AMP system and *Drosophila* learning. *Mol Cell Biochem* 149-150:271-278.
- Davis RL, Takayasu H, Eberwine M, and Myres J. 1989. Cloning and characterization of mammalian homologs of the *Drosophila* dunce+ gene. *Proc Natl Acad Sci U S A* 86:3604-3608.
- Davoren PR and Sutherland EW. 1963. Effect of L-Epinephrine and Other Agents on Synthesis and Release of Adenosine 3',5'-Phosphate by Whole Pigeon Erythrocytes. *Journal of Biological Chemistry* 238:3009-&.
- de Rooij J, Zwartkruis FJ, Verheijen MH, Cool RH, Nijman SM, Wittinghofer A, and Bos JL. 1998. Epac is a Rap1 guanine-nucleotide-exchange factor directly activated by cyclic AMP. *Nature* 396:474-477.
- de Vente J. 2004. cGMP: a second messenger for acetylcholine in the brain? *Neurochem Int* 45:799-812.
- de Vente J, Hopkins DA, Markerink-Van Ittersum M, Emson PC, Schmidt HH, and Steinbusch HW. 1998. Distribution of nitric oxide synthase

- and nitric oxide-receptive, cyclic GMP-producing structures in the rat brain. *Neuroscience* 87:207-241.
- de Vente J, Markerink-Van Ittersum M, Axer H, and Steinbusch HW. 2001. Nitric-oxide-induced cGMP synthesis in cholinergic neurons in the rat brain. *Exp Brain Res* 136:480-491.
- Defer N, Best-Belpomme M, and Hanoune J. 2000. Tissue specificity and physiological relevance of various isoforms of adenylyl cyclase. *Am J Physiol Renal* 279:F400-F416.
- Degerman E, Belfrage P, and Manganiello VC. 1997. Structure, localization, and regulation of cGMP-inhibited phosphodiesterase (PDE3). *J Biol Chem* 272:6823-6826.
- Degerman E, Manganiello VC, Newman AH, Rice KC, and Belfrage P. 1988. Purification, properties and polyclonal antibodies for the particulate, low Km cAMP phosphodiesterase from bovine adipose tissue. *Second Messengers Phosphoproteins* 12:171-182.
- Del Maschio A, De Luigi A, Martin-Padura I, Brockhaus M, Bartfai T, Fruscella P, Adorini L, Martino G, Furlan R, De Simoni MG, and Dejana E. 1999. Leukocyte recruitment in the cerebrospinal fluid of mice with experimental meningitis is inhibited by an antibody to junctional adhesion molecule (JAM). *J Exp Med* 190:1351-1356.
- Denninger JW and Marletta MA. 1999. Guanylate cyclase and the .NO/cGMP signaling pathway. *Biochim Biophys Acta* 1411:334-350.
- Dent G and Giembycz MA. 1996. Phosphodiesterase inhibitors: Lily the Pink's medicinal compound for asthma? *Thorax* 51:647-649.
- Dietrich JB. 2002. The adhesion molecule ICAM-1 and its regulation in relation with the blood-brain barrier. *J Neuroimmunol* 128:58-68.
- Dinter H, Tse J, Halks-Miller M, Asarnow D, Onuffer J, Faulds D, Mitrovic B, Kirsch G, Laurent H, Esperling P, Seidelmann D, Ottow E, Schneider H, Tuohy VK, Wachtel H, and Perez HD. 2000. The type IV phosphodiesterase specific inhibitor mesopram inhibits experimental autoimmune encephalomyelitis in rodents. *J Neuroimmunol* 108:136-146.
- Dodge KL, Khouangsathiene S, Kapiloff MS, Mouton R, Hill EV, Houslay MD, Langeberg LK, and Scott JD. 2001. mAKAP assembles a protein kinase A/PDE4 phosphodiesterase cAMP signaling module. *EMBO J* 20:1921-1930.
- Dodge-Kafka KL, Soughayer J, Pare GC, Carlisle Michel JJ, Langeberg LK, Kapiloff MS, and Scott JD. 2005. The protein kinase A anchoring protein mAKAP coordinates two integrated cAMP effector pathways. *Nature* 437:574-578.
- Domek-Lopacinska K, Markerink-Van Ittersum M, Steinbusch HW, de Vente J. 2005a. Changes in expression of cGMP selective phosphodiesterases 2, 5 and 9 in the rat brain during aging. *BMC Pharmacol* 5 (Suppl 1), 15.
- Ref Type: Journal (Full)
- Domek-Lopacinska K, van de WM, Markerink-Van Ittersum M, Steinbusch HW, and de Vente J. 2005b. Nitric oxide-induced cGMP synthesis in the cholinergic system during the development and aging of the rat brain. *Brain Res Dev Brain Res* 158:72-81.
- Dousa TP. 1999. Cyclic-3',5'-nucleotide phosphodiesterase isozymes in cell biology and pathophysiology of the kidney. *Kidney Int* 55:29-62.
- Dudai Y, Jan YN, Byers D, Quinn WG, and Benzer S. 1976. dunce, a mutant of *Drosophila* deficient in learning. *Proc Natl Acad Sci U S A* 73:1684-1688.
- Dumaz N and Marais R. 2005. Integrating signals between cAMP and the RAS/RAF/MEK/ERK signalling pathways. Based on the anniversary prize of the Gesellschaft für Biochemie und Molekularbiologie Lecture delivered on 5 July 2003 at the Special FEBS Meeting in Brussels. *FEBS J* 272:3491-3504.
- Dunkern TR and Hatzelmann A. 2005. The effect of Sildenafil on human platelet secretory function is controlled by a complex interplay between phosphodiesterases 2, 3 and 5. *Cell Signal* 17:331-339.
- Duplantier AJ, Biggers MS, Chambers RJ, Cheng JB, Cooper K, Damon DB, Egger JF, Kraus KG, Marfat A, Masamune H, Pillar JS, Shirley JT, Umland JP, and Watson JW. 1996. Biarylcarboxylic acids and -amides: inhibition of phosphodiesterase type IV versus [3H]rolipram binding activity and their relationship to emetic behavior in the ferret. *J Med Chem* 39:120-125.
- Duzic E and Lanier SM. 1992. Factors Determining the Specificity of Signal Transduction by Guanine Nucleotide-Binding Protein-Coupled Receptors .3. Coupling of Alpha-2-Adrenergic Receptor Subtypes in A Cell Type-Specific Manner. *Journal of Biological Chemistry* 267:24045-24052.
- Dyke HJ and Montana JG. 2002. Update on the therapeutic potential of PDE4 inhibitors. *Exp Opin Invest Drugs* 11:1-13.
- Eason MG and Liggett SB. 1995. Identification of A G(S) Coupling Domain in the Amino-Terminus of the 3Rd Intracellular Loop of the Alpha(2A)-Adrenergic Receptor - Evidence for Distinct Structural Determinants That Confer G(S) Versus G(I) Coupling. *Journal of Biological Chemistry* 270:24753-24760.
- Eigler A, Siegmund B, Emmerich U, Baumann KH, Hartmann G, and Endres S. 1998. Anti-inflammatory activities of cAMP-elevating agents: enhancement of IL-10 synthesis and concurrent suppression of TNF production. *J Leukoc Biol* 63:101-107.
- El Bawab S, Macovschi O, Sette C, Conti M, Lagarde M, Nemoz G, and Prigent AF. 1997. Selective stimulation of a cAMP-specific phosphodiesterase (PDE4A5) isoform by phosphatidic acid molecular species endogenously formed in rat thymocytes. *Eur J Biochem* 247:1151-1157.

- El Husseini AED, Williams J, Reiner PB, Pelech S, and Vincent SR. 1999. Localization of the cGMP-dependent protein kinases in relation to nitric oxide synthase in the brain. *Journal of Chemical Neuroanatomy* 17:45-55.
- Elmqvist JK, Breder CD, Sherin JE, Scammell TE, Hickey WF, Dewitt D, and Saper CB. 1997. Intravenous lipopolysaccharide induces cyclooxygenase 2-like immunoreactivity in rat brain perivascular microglia and meningeal macrophages. *J Comp Neurol* 381:119-129.
- Elmqvist JK, Scammell TE, Jacobson CD, and Saper CB. 1996. Distribution of Fos-like immunoreactivity in the rat brain following intravenous lipopolysaccharide administration. *J Comp Neurol* 371:85-103.
- Elson G, Dunn-Siegrist I, Daubeuf B, and Pugin J. 2007. Contribution of Toll-like receptors to the innate immune response to Gram-negative and Gram-positive bacteria. *Blood* 109:1574-1583.
- Endo H, Sasaki K, Tonosaki A, and Kayama T. 1998. Three-dimensional and ultrastructural ICAM-1 distribution in the choroid plexus, arachnoid membrane and dural sinus of inflammatory rats induced by LPS injection in the lateral ventricles. *Brain Res* 793:297-301.
- Engelhardt B, Wolburg-Buchholz K, and Wolburg H. 2001. Involvement of the choroid plexus in central nervous system inflammation. *Microsc Res Tech* 52:112-129.
- Engels P, Abdel'Al S, Hulley P, and Lubbert H. 1995a. Brain distribution of four rat homologues of the *Drosophila dunce* cAMP phosphodiesterase. *J Neurosci Res* 41:169-178.
- Engels P, Fichtel K, and Lubbert H. 1994. Expression and regulation of human and rat phosphodiesterase type IV isogenes. *FEBS Lett* 350:291-295.
- Engels P, Sullivan M, Muller T, and Lubbert H. 1995b. Molecular cloning and functional expression in yeast of a human cAMP-specific phosphodiesterase subtype (PDE IV-C). *FEBS Lett* 358:305-310.
- Essayan DM. 1999. Cyclic nucleotide phosphodiesterase (PDE) inhibitors and immunomodulation. *Biochem Pharmacol* 57:965-973.
- Estevez AG, Spear N, Thompson JA, Cornwell TL, Radi R, Barbeito L, and Beckman JS. 1998. Nitric oxide-dependent production of cGMP supports the survival of rat embryonic motor neurons cultured with brain-derived neurotrophic factor. *J Neurosci* 18:3708-3714.
- Fallis RJ, Raine CS, and McFarlin DE. 1989. Chronic relapsing experimental allergic encephalomyelitis in SJL mice following the adoptive transfer of an epitope-specific T cell line. *J Neuroimmunol* 22:93-105.
- Farber DB and Tsang SH. 2003. Stationary night blindness or progressive retinal degeneration in mice carrying different alleles of PDE gamma. *Front Biosci* 8:s666-s675.
- Farooqui AA and Horrocks LA. 2004. Brain phospholipases A2: a perspective on the history. *Prostaglandins Leukot Essent Fatty Acids* 71:161-169.
- Favot L, Keravis T, and Lugnier C. 2004. Modulation of VEGF-induced endothelial cell cycle protein expression through cyclic AMP hydrolysis by PDE2 and PDE4. *Thromb Haemost* 92:634-645.
- Fawcett L, Baxendale R, Stacey P, McGrouther C, Harrow I, Soderling S, Hetman J, Beavo JA, and Phillips SC. 2000. Molecular cloning and characterization of a distinct human phosphodiesterase gene family: PDE11A. *Proc Natl Acad Sci U S A* 97:3702-3707.
- Fearns C, Kravchenko VV, Ulevitch RJ, and Loskutoff DJ. 1995. Murine CD14 gene expression in vivo: extramyeloid synthesis and regulation by lipopolysaccharide. *J Exp Med* 181:857-866.
- Federman AD, Conklin BR, Schrader KA, Reed RR, and Bourne HR. 1992. Hormonal stimulation of adenylyl cyclase through Gi-protein beta gamma subunits. *Nature* 356:159-161.
- Fedoroff S, Zhai R, and Novak JP. 1997. Microglia and astroglia have a common progenitor cell. *J Neurosci Res* 50:477-486.
- Fierz W, Endler B, Reske K, Wekerle H, and Fontana A. 1985. Astrocytes as antigen-presenting cells. I. Induction of Ia antigen expression on astrocytes by T cells via immune interferon and its effect on antigen presentation. *J Immunol* 134:3785-3793.
- Fischmeister R, Castro L, Abi-Gerges A, Rochais F, and Vandecasteele G. 2005. Species- and tissue-dependent effects of NO and cyclic GMP on cardiac ion channels. *Comp Biochem Physiol A Mol Integr Physiol* 142:136-143.
- Fischmeister R and Mery PF. 1996. [Regulation of cardiac calcium current by cGMP/NO route]. *C R Seances Soc Biol Fil* 190:181-206.
- Fisher DA, Smith JF, Pillar JS, St Denis SH, and Cheng JB. 1998a. Isolation and characterization of PDE8A, a novel human cAMP-specific phosphodiesterase. *Biochem Biophys Res Commun* 246:570-577.
- Fisher DA, Smith JF, Pillar JS, St Denis SH, and Cheng JB. 1998b. Isolation and characterization of PDE9A, a novel human cGMP-specific phosphodiesterase. *J Biol Chem* 273:15559-15564.
- Fitzpatrick JJ, Stier L, Eichorn A, Dlugacz YD, O'Connor LJ, Salinas TK, Smith T, and White MT. 2004. Hospitalized elders: changes in functional and mental status. *Outcomes Manag* 8:52-56.
- Fleming YM, Frame MC, and Houslay MD. 2004. PDE4-regulated cAMP degradation controls the assembly of integrin-dependent actin adhesion structures and REF52 cell migration. *J Cell Sci* 117:2377-2388.
- Floris S, Blezer EL, Schreiber G, Dopp E, van der Pol SM, Schadee-Eestermans IL, Nicolay K, Dijkstra CD, and de Vries HE. 2004. Blood-brain barrier permeability and monocyte infiltration in experimental allergic

- encephalomyelitis: a quantitative MRI study. *Brain* 127:616-627.
- Forstermann U, Boissel JP, and Kleinert H. 1998. Expressional control of the 'constitutive' isoforms of nitric oxide synthase (NOS I and NOS III). *FASEB J* 12:773-790.
- Foster DC, Wedel BJ, Robinson SW, and Garbers DL. 1999. Mechanisms of regulation and functions of guanylyl cyclases. *Rev Physiol Biochem Pharmacol* 135:1-39.
- Francis SH, Bessay EP, Kotera J, Grimes KA, Liu L, Thompson WJ, and Corbin JD. 2002a. Phosphorylation of isolated human phosphodiesterase-5 regulatory domain induces an apparent conformational change and increases cGMP binding affinity. *J Biol Chem* 277:47581-47587.
- Francis SH and Corbin JD. 1994. Structure and function of cyclic nucleotide-dependent protein kinases. *Annu Rev Physiol* 56:237-272.
- Francis SH, Lincoln TM, and Corbin JD. 1980. Characterization of a novel cGMP binding protein from rat lung. *J Biol Chem* 255:620-626.
- Francis SH, Noblett BD, Todd BW, Wells JN, and Corbin JD. 1988. Relaxation of Vascular and Tracheal Smooth-Muscle by Cyclic-Nucleotide Analogs That Preferentially Activate Purified Cgmp-Dependent Protein-Kinase. *Molecular Pharmacology* 34:506-517.
- Francis SH, Turko IV, and Corbin JD. 2001. Cyclic nucleotide phosphodiesterases: relating structure and function. *Prog Nucleic Acid Res Mol Biol* 65:1-52.
- Francis SH, Turko IV, and Corbin JD. 2002b. Cyclic nucleotide phosphodiesterases: relating structure and function. *Prog Nucleic Acid Res Mol Biol* 65:1-52.
- Frazer A. 1997. Pharmacology of antidepressants. *J Clin Psychopharmacol* 17 Suppl 1:2S-18S.
- Fredriksson R, Lagerstrom MC, Lundin LG, and Schioth HB. 2003. The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints. *Mol Pharmacol* 63:1256-1272.
- Frenette R, Blouin M, Brideau C, Chauret N, Ducharme Y, Friesen RW, Hamel P, Jones TR, Laliberte F, Li C, Masson P, McAuliffe M, and Girard Y. 2002. Substituted 4-(2,2-diphenylethyl)pyridine-N-oxides as phosphodiesterase-4 inhibitors: SAR study directed toward the improvement of pharmacokinetic parameters. *Bioorg Med Chem Lett* 12:3009-3013.
- Frey U, Huang YY, and Kandel ER. 1993. Effects of cAMP simulate a late stage of LTP in hippocampal CA1 neurons. *Science* 260:1661-1664.
- Friedman WJ, Larkfors L, Ayer-LeLievre C, Ebendal T, Olson L, and Persson H. 1990. Regulation of beta-nerve growth factor expression by inflammatory mediators in hippocampal cultures. *J Neurosci Res* 27:374-382.
- Fritz RB and McFarlin DE. 1989. Encephalitogenic epitopes of myelin basic protein. *Chem Immunol* 46:101-125.
- Fujino M, Funeshima N, Kitazawa Y, Kimura H, Amemiya H, Suzuki S, and Li XK. 2003. Amelioration of experimental autoimmune encephalomyelitis in lewis rats by FTY720 treatment. *Journal of Pharmacology and Experimental Therapeutics* 305:70-77.
- Fujishige K, Kotera J, Michibata H, Yuasa K, Takebayashi S, Okumura K, and Omori K. 1999a. Cloning and characterization of a novel human phosphodiesterase that hydrolyzes both cAMP and cGMP (PDE10A). *J Biol Chem* 274:18438-18445.
- Fujishige K, Kotera J, and Omori K. 1999b. Striatum- and testis-specific phosphodiesterase PDE10A isolation and characterization of a rat PDE10A [In Process Citation]. *Eur J Biochem* 266:1118-1127.
- Fujishige K, Kotera J, Yuasa K, and Omori K. 2000. The human phosphodiesterase PDE10A gene genomic organization and evolutionary relatedness with other PDEs containing GAF domains. *Eur J Biochem* 267:5943-5951.
- Furchgott RF and Zawadzki JV. 1980. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. *Nature* 288:373-376.
- Furuyama T, Inagaki S, and Takagi H. 1993a. Distribution of type II adenylyl cyclase mRNA in the rat brain. *Mol Brain Res* 19:165-170.
- Furuyama T, Inagaki S, and Takagi H. 1993b. Localizations of Alpha-1-Subunit and Beta-1-Subunit of Soluble Guanylate-Cyclase in the Rat-Brain. *Molecular Brain Research* 20:335-344.
- Gal A, Orth U, Baehr W, Schwinger E, and Rosenberg T. 1994. Heterozygous missense mutation in the rod cGMP phosphodiesterase beta-subunit gene in autosomal dominant stationary night blindness. *Nat Genet* 7:64-68.
- Galperin MY, Nikolskaya AN, and Koonin EV. 2001. Novel domains of the prokaryotic two-component signal transduction systems. *FEMS Microbiol Lett* 203:11-21.
- Gamanuma M, Yuasa K, Sasaki T, Sakurai N, Kotera J, and Omori K. 2003. Comparison of enzymatic characterization and gene organization of cyclic nucleotide phosphodiesterase 8 family in humans. *Cell Signal* 15:565-574.
- Gantner F, Gotz C, Gekeler V, Schudt C, Wendel A, and Hatzelmann A. 1998. Phosphodiesterase profile of human B lymphocytes from normal and atopic donors and the effects of PDE inhibition on B cell proliferation. *Br J Pharmacol* 123:1031-1038.
- Garcia-Jimenez A, Cowburn RF, Ohm TG, Bogdanovic N, Winblad B, and Fastbom J. 1999. Quantitative autoradiography of [3H]forskolin binding sites in post-mortem brain staged for Alzheimer's disease neurofibrillary changes and amyloid deposits. *Brain Res* 850:104-117.

## Bibliografía

- Gardner C, Robas N, Cawkill D, and Fidock M. 2000. Cloning and characterization of the human and mouse PDE7B, a novel cAMP-specific cyclic nucleotide phosphodiesterase. *Biochem Biophys Res Commun* 272:186-192.
- Garthwaite J. 1991. Glutamate, nitric oxide and cell-cell signalling in the nervous system. *Trends Neurosci* 14:60-67.
- Garthwaite J. 1995. Neural nitric oxide signalling. *Trends Neurosci* 18:51-52.
- Garthwaite J and Boulton CL. 1995. Nitric oxide signaling in the central nervous system. *Annu Rev Physiol* 57:683-706.
- Garthwaite J, Garthwaite G, Palmer RM, and Moncada S. 1989. NMDA receptor activation induces nitric oxide synthesis from arginine in rat brain slices. *Eur J Pharmacol* 172:413-416.
- Gehrmann J, Mies G, Bonnekoh P, Banati R, Iijima T, Kreutzberg GW, and Hossmann KA. 1993. Microglial reaction in the rat cerebral cortex induced by cortical spreading depression. *Brain Pathol* 3:11-17.
- Genain CP, Roberts T, Davis RL, Nguyen MH, Uccelli A, Faulds D, Li Y, Hedgpeth J, and Hauser SL. 1995. Prevention of autoimmune demyelination in non-human primates by a cAMP-specific phosphodiesterase inhibitor. *Proc Natl Acad Sci U S A* 92:3601-3605.
- Gether U. 2000. Uncovering molecular mechanisms involved in activation of G protein-coupled receptors. *Endocr Rev* 21:90-113.
- Ghera P, Hooff vH, Whelan J, Cambet Y, Pescini R, and DeLamarter JF. 1994. Inhibition of E-selectin gene transcription through a cAMP-dependent protein kinase pathway. *J Biol Chem* 269:29129-29137.
- Giembycz MA. 2000. Phosphodiesterase 4 inhibitors and the treatment of asthma: where are we now and where do we go from here? *Drugs* 59:193-212.
- Giembycz MA, Corrigan CJ, Seybold J, Newton R, and Barnes PJ. 1996. Identification of cyclic AMP phosphodiesterases 3, 4 and 7 in human CD4+ and CD8+ T-lymphocytes: role in regulating proliferation and the biosynthesis of interleukin-2. *Br J Pharmacol* 118:1945-1958.
- Gilles-Gonzalez MA and Gonzalez G. 2004. Signal transduction by heme-containing PAS-domain proteins. *J Appl Physiol* 96:774-783.
- Gillespie PG and Beavo JA. 1988. Characterization of a bovine cone photoreceptor phosphodiesterase purified by cyclic GMP-sepharose chromatography. *J Biol Chem* 263:8133-8141.
- Giordano D, De Stefano ME, Citro G, Modica A, and Giorgi M. 2001. Expression of cGMP-binding cGMP-specific phosphodiesterase (PDE5) in mouse tissues and cell lines using an antibody against the enzyme amino-terminal domain. *Biochim Biophys Acta* 1539:16-27.
- Glabinski AR, Tuohy VK, and Ransohoff RM. 1998. Expression of chemokines RANTES, MIP-1alpha and GRO-alpha correlates with inflammation in acute experimental autoimmune encephalomyelitis. *Neuroimmunomodulation* 5:166-171.
- Glavas NA, Ostenson C, Schaefer JB, Vasta V, and Beavo JA. 2001. T cell activation up-regulates cyclic nucleotide phosphodiesterases 8A1 and 7A3. *Proc Natl Acad Sci U S A* 98:6319-6324.
- Gong Y, Chang L, Viola KL, Lacor PN, Lambert MP, Finch CE, Krafft GA, and Klein WL. 2003. Alzheimer's disease-affected brain: presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss. *Proc Natl Acad Sci U S A* 100:10417-10422.
- Goodwin JS and Ceuppens J. 1983. Regulation of the Immune-Response by Prostaglandins. *Journal of Clinical Immunology* 3:295-315.
- Gordon EJ, Myers KJ, Dougherty JP, Rosen H, and Ron Y. 1995. Both anti-CD11a (LFA-1) and anti-CD11b (MAC-1) therapy delay the onset and diminish the severity of experimental autoimmune encephalomyelitis. *J Neuroimmunol* 62:153-160.
- Gouault N, Martin-Chouly CA, Lugnier C, Cupif JF, Tonnelier A, Feger F, Lagente V, and David M. 2004. Solid-phase synthesis and evaluation of libraries of substituted 4,5-dihydropyridazinones as vasodilator agents. *J Pharm Pharmacol* 56:1029-1037.
- Greenwood J, Wang Y, and Calder VL. 1995. Lymphocyte adhesion and transendothelial migration in the central nervous system: the role of LFA-1, ICAM-1, VLA-4 and VCAM-1. *off. Immunology* 86:408-415.
- Grigoriadis N, Tselios T, Deraos S, Orolagas A, Deraos G, Matsoukas J, Mavromatis L, and Milonas I. 2005. Animal models of central nervous system immune-mediated diseases: Therapeutic interventions with bioactive peptides and mimetics. *Current Medicinal Chemistry* 12:1513-1519.
- Gross SS and Wolin MS. 1995. Nitric oxide: pathophysiological mechanisms. *Annu Rev Physiol* 57:737-769.
- Gross-Langenhoff M, Hofbauer K, Weber J, Schultz A, and Schultz JE. 2006. cAMP is a ligand for the tandem GAF domain of human phosphodiesterase 10 and cGMP for the tandem GAF domain of phosphodiesterase 11. *J Biol Chem* 281:2841-2846.
- Gudermann T, Kalkbrenner F, and Schultz G. 1996. Diversity and selectivity of receptor-G protein interaction. *Annu Rev Pharmacol Toxicol* 36:429-459.
- Guipponi M, Scott HS, Kudoh J, Kawasaki K, Shibuya K, Shintani A, Asakawa S, Chen H, Lalioti MD, Rossier C, Minoshima S, Shimizu N, and Antonarakis SE. 1998. Identification and characterization of a novel cyclic nucleotide phosphodiesterase gene (PDE9A) that maps to 21q22.3: alternative splicing of mRNA transcripts, genomic structure and sequence. *Hum Genet* 103:386-392.
- Halbrugge M, Friedrich C, Eigenthaler M, Schanzenbacher P, and Walter U. 1990. Stoichiometric and Reversible Phosphorylation of A 46-Kda Protein in Human Platelets in

- Response to Cgmp-Elevating and Camp-Elevating Vasodilators. *Journal of Biological Chemistry* 265:3088-3093.
- Han P, Werber J, Surana M, Fleischer N, and Michaeli T. 1999. The calcium/calmodulin-dependent phosphodiesterase PDE1C down-regulates glucose-induced insulin secretion. *Journal of Biological Chemistry* 274:22337-22344.
- Han P, Zhu X, and Michaeli T. 1997. Alternative splicing of the high affinity cAMP-specific phosphodiesterase (PDE7A) mRNA in human skeletal muscle and heart. *J Biol Chem* 272:16152-16157.
- Hanoune J and Defer N. 2001. Regulation and role of adenylyl cyclase isoforms. *Annu Rev Pharmacol Toxicol* 41:145-174.
- Hanoune J, Pouille Y, Tzavara E, Shen T, Lipskaya L, Miyamoto N, Suzuki Y, and Defer N. 1997. Adenylyl cyclases: structure, regulation and function in an enzyme superfamily. *Mol Cell Endocrinol* 128:179-194.
- Hansen G, Jin S, Umetsu DT, and Conti M. 2000. Absence of muscarinic cholinergic airway responses in mice deficient in the cyclic nucleotide phosphodiesterase PDE4D [In Process Citation]. *Proc Natl Acad Sci U S A* 97:6751-6756.
- Hardman JG and Sutherland EW. 1969. Guanyl cyclase, an enzyme catalyzing the formation of guanosine 3',5'-monophosphate from guanosine triphosphate. *J Biol Chem* 244:6363-6370.
- Harrison JK, Jiang Y, Chen S, Xia Y, Maciejewski D, McNamara RK, Streit WJ, Salafranca MN, Adhikari S, Thompson DA, Botti P, Bacon KB, and Feng L. 1998. Role for neuronally derived fractalkine in mediating interactions between neurons and CX3CR1-expressing microglia. *Proc Natl Acad Sci U S A* 95:10896-10901.
- Harrison SA, Reifsnnyder DH, Gallis B, Cadd GG, and Beavo JA. 1986. Isolation and characterization of bovine cardiac muscle cGMP-inhibited phosphodiesterase: a receptor for new cardiotoxic drugs. *Mol Pharmacol* 29:506-514.
- Hayashi M, Matsushima K, Ohashi H, Tsunoda H, Murase S, Kawarada Y, and Tanaka T. 1998. Molecular cloning and characterization of human PDE8B, a novel thyroid-specific isozyme of 3',5'-cyclic nucleotide phosphodiesterase. *Biochem Biophys Res Commun* 250:751-756.
- Hayashi M, Shimada Y, Nishimura Y, Hama T, and Tanaka T. 2002. Genomic organization, chromosomal localization, and alternative splicing of the human phosphodiesterase 8B gene. *Biochem Biophys Res Commun* 297:1253-1258.
- Haynes L and Yau KW. 1985. Cyclic Gmp-Sensitive Conductance in Outer Segment Membrane of Catfish Cones. *Nature* 317:61-64.
- Hebb AL, Robertson HA, and Denovan-Wright EM. 2004. Striatal phosphodiesterase mRNA and protein levels are reduced in Huntington's disease transgenic mice prior to the onset of motor symptoms. *Neuroscience* 123:967-981.
- Hendrix M. 2005. Selective inhibitors of cGMP phosphodiesterases as procognitive agents. *BMC Pharmacol* 5 (Suppl. 1) S5.
- Hetman JM, Robas N, Baxendale R, Fidock M, Phillips SC, Soderling SH, and Beavo JA. 2000a. Cloning and characterization of two splice variants of human phosphodiesterase 11A. *Proc Natl Acad Sci U S A* 97:12891-12895.
- Hetman JM, Soderling SH, Glavas NA, and Beavo JA. 2000b. Cloning and characterization of PDE7B, a cAMP-specific phosphodiesterase. *Proc Natl Acad Sci U S A* 97:472-476.
- Hickey WF. 1999. Leukocyte traffic in the central nervous system: the participants and their roles. *Semin Immunol* 11:125-137.
- Hickey WF, Vass K, and Lassmann H. 1992. Bone marrow-derived elements in the central nervous system: an immunohistochemical and ultrastructural survey of rat chimeras. *J Neuropathol Exp Neurol* 51:246-256.
- Hildebrandt JD. 1997. Role of subunit diversity in signaling by heterotrimeric G proteins. *Biochem Pharmacol* 54:325-339.
- Hirrlinger J, Konig J, and Dringen R. 2002. Expression of mRNAs of multidrug resistance proteins (Mrps) in cultured rat astrocytes, oligodendrocytes, microglial cells and neurones. *Journal of Neurochemistry* 82:716-719.
- Hobbs AJ. 1997. Soluble guanylate cyclase: the forgotten sibling. *Trends Pharmacol Sci* 18:484-491.
- Hoeper MM. 2005. Drug treatment of pulmonary arterial hypertension: current and future agents. *Drugs* 65:1337-1354.
- Hoffmann R, Abdel'Al S, and Engels P. 1998a. Differential distribution of rat PDE-7 mRNA in embryonic and adult rat brain. *Cell Biochem Biophys* 28:103-113.
- Hoffmann R, Baillie GS, MacKenzie SJ, Yarwood SJ, and Houslay MD. 1999. The MAP kinase ERK2 inhibits the cyclic AMP-specific phosphodiesterase HSPDE4D3 by phosphorylating it at Ser579. *EMBO J* 18:893-903.
- Hoffmann R, Wilkinson IR, McCallum JF, Engels P, and Houslay MD. 1998b. cAMP-specific phosphodiesterase HSPDE4D3 mutants which mimic activation and changes in rolipram inhibition triggered by protein kinase A phosphorylation of Ser-54: generation of a molecular model. *Biochem J* 333 ( Pt 1):139-149.
- Hong KW, Lee JH, Kim KY, Park SY, and Lee WS. 2006. Cilostazol: Therapeutic potential against focal cerebral ischemic damage. *Current Pharmaceutical Design* 12:565-573.
- Hopkins SJ. 2007. Central nervous system recognition of peripheral inflammation: a neural, hormonal collaboration. *Acta Biomed* 78 Suppl 1:231-247.
- Horton YM, Sullivan M, and Houslay MD. 1995. Molecular cloning of a novel splice variant of

- human type IVA (PDE-IVA) cyclic AMP phosphodiesterase and localization of the gene to the p13.2- q12 region of human chromosome 19 [corrected] [published erratum appears in *Biochem J* 1995 Dec 15;312(Pt 3):991]. *Biochem J* 308 ( Pt 2):683-691.
- Houslay MD. 1995. Compartmentalization of cyclic AMP phosphodiesterases, signalling 'crosstalk', desensitization and the phosphorylation of Gi-2 add cell specific personalization to the control of the levels of the second messenger cyclic AMP. *Adv Enzyme Regul* 35:303-338.
- Houslay MD. 1998. Adaptation in cyclic AMP signalling processes: a central role for cyclic AMP phosphodiesterases. *Semin Cell Dev Biol* 9:161-167.
- Houslay MD. 2001. PDE4 cAMP-specific phosphodiesterases. *Prog Nucleic Acid Res Mol Biol* 69:249-315.
- Houslay MD and Adams DR. 2003. PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization. *Biochem J* 370:1-18.
- Houslay MD and Kolch W. 2000. Cell-type specific integration of cross-talk between extracellular signal-regulated kinase and cAMP signaling. *Mol Pharmacol* 58:659-668.
- Houslay MD and Milligan G. 1997. Tailoring cAMP-signalling responses through isoform multiplicity. *Trends Biochem Sci* 22:217-224.
- Houslay MD, Schafer P, and Zhang KY. 2005. Keynote review: phosphodiesterase-4 as a therapeutic target. *Drug Discov Today* 10:1503-1519.
- Houslay MD, Sullivan M, and Bolger GB. 1998. The multienzyme PDE4 cyclic adenosine monophosphate-specific phosphodiesterase family: intracellular targeting, regulation, and selective inhibition by compounds exerting anti-inflammatory and antidepressant actions. *Adv Pharmacol* 44:225-342.
- Howard KM and Olson MS. 2000. The expression and localization of plasma platelet-activating factor acetylhydrolase in endotoxemic rats. *J Biol Chem* 275:19891-19896.
- Hu H, McCaw EA, Hebb AL, Gomez GT, and Denovan-Wright EM. 2004. Mutant huntingtin affects the rate of transcription of striatum-specific isoforms of phosphodiesterase 10A. *Eur J Neurosci* 20:3351-3363.
- Huai Q, Colicelli J, and Ke H. 2003. The crystal structure of AMP-bound PDE4 suggests a mechanism for phosphodiesterase catalysis. *Biochemistry* 42:13220-13226.
- Huang Z, Ducharme Y, Macdonald D, and Robichaud A. 2001. The next generation of PDE4 inhibitors. *Curr Opin Chem Biol* 5:432-438.
- Humpl T, Reyes JT, Holtby H, Stephens D, and Adatia I. 2005. Beneficial effect of oral sildenafil therapy on childhood pulmonary arterial hypertension: twelve-month clinical trial of a single-drug, open-label, pilot study. *Circulation* 111:3274-3280.
- Huston E, Beard M, McCallum F, Pyne NJ, Vandenabeele P, Scotland G, and Houslay MD. 2000. The cAMP-specific phosphodiesterase PDE4A5 is cleaved downstream of its SH3 interaction domain by caspase-3. Consequences for altered intracellular distribution. *J Biol Chem* 275:28063-28074.
- Huston E, Lumb S, Russell A, Catterall C, Ross AH, Steele MR, Bolger GB, Perry MJ, Owens RJ, and Houslay MD. 1997. Molecular cloning and transient expression in COS7 cells of a novel human PDE4B cAMP-specific phosphodiesterase, HSPDE4B3. *Biochem J* 328 ( Pt 2):549-558.
- Huston E, Pooley L, Julien P, Scotland G, McPhee I, Sullivan M, Bolger G, and Houslay MD. 1996. The human cyclic AMP-specific phosphodiesterase PDE-46 (HSPDE4A4B) expressed in transfected COS7 cells occurs as both particulate and cytosolic species that exhibit distinct kinetics of inhibition by the antidepressant rolipram. *J Biol Chem* 271:31334-31344.
- Ibrahim SM, Mix E, Bottcher T, Koczan D, Gold R, Rolfs A, and Thiesen HJ. 2001. Gene expression profiling of the nervous system in murine experimental autoimmune encephalomyelitis. *Brain* 124:1927-1938.
- Ichimura M and Kase H. 1993. A new cyclic nucleotide phosphodiesterase isozyme expressed in the T- lymphocyte cell lines. *Biochem Biophys Res Commun* 193:985-990.
- Ignarro LJ, Buga GM, Wood KS, Byrns RE, and Chaudhuri G. 1987a. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. *Proc Natl Acad Sci U S A* 84:9265-9269.
- Ignarro LJ, Byrns RE, Buga GM, and Wood KS. 1987b. Endothelium-derived relaxing factor from pulmonary artery and vein possesses pharmacologic and chemical properties identical to those of nitric oxide radical. *Circ Res* 61:866-879.
- Issazadeh S, Ljungdahl A, Hojeberg B, Mustafa M, and Olsson T. 1995a. Cytokine production in the central nervous system of Lewis rats with experimental autoimmune encephalomyelitis: dynamics of mRNA expression for interleukin-10, interleukin-12, cytolysin, tumor necrosis factor alpha and tumor necrosis factor beta. *J Neuroimmunol* 61:205-212.
- Issazadeh S, Mustafa M, Ljungdahl A, Hojeberg B, Dagerlind A, Elde R, and Olsson T. 1995b. Interferon gamma, interleukin 4 and transforming growth factor beta in experimental autoimmune encephalomyelitis in Lewis rats: dynamics of cellular mRNA expression in the central nervous system and lymphoid cells. *J Neurosci Res* 40:579-590.
- Ito M, Nishikawa M, Fujioka M, Miyahara M, Isaka N, Shiku H, and Nakano T. 1996. Characterization of the isoenzymes of cyclic nucleotide phosphodiesterase in human platelets and the effects of E4021. *Cell Signal* 8:575-581.

- Iwahashi Y, Furuyama T, Tano Y, Ishimoto I, Shimomura Y, and Inagaki S. 1996. Differential distribution of mRNA encoding cAMP-specific phosphodiesterase isoforms in the rat brain. *Mol Brain Res* 38:14-24.
- Iyengar R. 1996. Gating by cyclic AMP: expanded role for an old signaling pathway. *Science* 271:461-463.
- Jacobitz S, McLaughlin MM, Livi GP, Burman M, and Torphy TJ. 1996. Mapping the functional domains of human recombinant phosphodiesterase 4A: structural requirements for catalytic activity and rolipram binding. *Mol Pharmacol* 50:891-899.
- Jacobitz S, Ryan MD, McLaughlin MM, Livi GP, DeWolf WEJ, and Torphy TJ. 1997. Role of conserved histidines in catalytic activity and inhibitor binding of human recombinant phosphodiesterase 4A. *Mol Pharmacol* 51:999-1006.
- Janeway CA, Jr. and Medzhitov R. 2002. Innate immune recognition. *Annu Rev Immunol* 20:197-216.
- Jarchau T, Hausler C, Markert T, Pohler D, Vandekerckhove J, Dejonge HR, Lohmann SM, and Walter U. 1994. Cloning, Expression, and In-Situ Localization of Rat Intestinal Cgmp-Dependent Protein-Kinase-ii. *Proceedings of the National Academy of Sciences of the United States of America* 91:9426-9430.
- Jedlitschky G, Burchell B, and Keppler D. 2000. The multidrug resistance protein 5 functions as an ATP-dependent export pump for cyclic nucleotides. *Journal of Biological Chemistry* 275:30069-30074.
- Jee Y, Liu RL, Bai XF, Campagnolo DI, Shi FD, and Vollmer TL. 2006. Do T(h)2 cells mediate the effects of glatiramer acetate in experimental autoimmune encephalomyelitis? *International Immunology* 18:537-544.
- Jeffery P. 2005. Phosphodiesterase 4-selective inhibition: novel therapy for the inflammation of COPD. *Pulm Pharmacol Ther* 18:9-17.
- Jin SL and Conti M. 2002. Induction of the cyclic nucleotide phosphodiesterase PDE4B is essential for LPS-activated TNF-alpha responses. *Proc Natl Acad Sci U S A* 99:7628-7633.
- Jin SL, Lan L, Zoudilova M, and Conti M. 2005a. Specific role of phosphodiesterase 4B in lipopolysaccharide-induced signaling in mouse macrophages. *J Immunol* 175:1523-1531.
- Jin SL, Latour AM, and Conti M. 2005b. Generation of PDE4 knockout mice by gene targeting. *Methods Mol Biol* 307:191-210.
- Jin SL, Richard FJ, Kuo WP, D'Ercole AJ, and Conti M. 1999. Impaired growth and fertility of cAMP-specific phosphodiesterase PDE4D-deficient mice. *Proc Natl Acad Sci U S A* 96:11998-12003.
- Jin SL, Swinnen JV, and Conti M. 1992. Characterization of the structure of a low Km, rolipram-sensitive cAMP phosphodiesterase. Mapping of the catalytic domain. *J Biol Chem* 267:18929-18939.
- Jordan FL and Thomas WE. 1988. Brain macrophages: questions of origin and interrelationship. *Brain Res* 472:165-178.
- Jordan JD and Iyengar R. 1998. Modes of interactions between signaling pathways. *Biochem Pharmacol* 55:1347-1352.
- Juilfs DM, Fulle HJ, Zhao AZ, Houslay MD, Garbers DL, and Beavo JA. 1997. A subset of olfactory neurons that selectively express cGMP-stimulated phosphodiesterase (PDE2) and guanylyl cyclase-D define a unique olfactory signal transduction pathway. *Proc Natl Acad Sci U S A* 94:3388-3395.
- Kajimura N, Yamazaki M, Morikawa K, Yamazaki A, and Mayanagi K. 2002. Three-dimensional structure of non-activated cGMP phosphodiesterase 6 and comparison of its image with those of activated forms. *J Struct Biol* 139:27-38.
- Kakkar R, Raju RV, Rajput AH, and Sharma RK. 1996. Inhibition of bovine brain calmodulin-dependent cyclic nucleotide phosphodiesterase isozymes by deprenyl. *Life Sci* 59:L337-L341.
- Kakkar R, Raju RV, and Sharma RK. 1999. Calmodulin-dependent cyclic nucleotide phosphodiesterase (PDE1). *Cell Mol Life Sci* 55:1164-1186.
- Kalyvas A and David S. 2004. Cytosolic phospholipase A2 plays a key role in the pathogenesis of multiple sclerosis-like disease. *Neuron* 41:323-335.
- Kambayashi J, Liu Y, Sun B, Shakur Y, Yoshitake M, and Czerwiec F. 2003. Cilostazol as a unique antithrombotic agent. *Curr Pharm Des* 9:2289-2302.
- Kammer GM, Boehm CA, Rudolph SA, and Schultz LA. 1988. Mobility of the human T lymphocyte surface molecules CD3, CD4, and CD8: regulation by a cAMP-dependent pathway. *Proc Natl Acad Sci U S A* 85:792-796.
- Kanda N and Watanabe S. 2001. Regulatory roles of adenylate cyclase and cyclic nucleotide phosphodiesterases 1 and 4 in interleukin-13 production by activated human T cells. *Biochem Pharmacol* 62:495-507.
- Kandel ER and Schwartz JH. 1982. Molecular biology of learning: modulation of transmitter release. *Science* 218:433-443.
- Karpus WJ and Ransohoff RM. 1998. Chemokine regulation of experimental autoimmune encephalomyelitis: temporal and spatial expression patterns govern disease pathogenesis. *J Immunol* 161:2667-2671.
- Kasuya J, Goko H, and Fujita-Yamaguchi Y. 1995. Multiple transcripts for the human cardiac form of the cGMP-inhibited cAMP phosphodiesterase. *J Biol Chem* 270:14305-14312.
- Katsuki H and Okuda S. 1995. Arachidonic acid as a neurotoxic and neurotrophic substance. *Prog Neurobiol* 46:607-636.
- Kaur C, Hao AJ, Wu CH, and Ling EA. 2001. Origin of microglia. *Microsc Res Tech* 54:2-9.



- Kawasaki H, Sprightgett GM, Toki S, Canales JJ, Harlan P, Blumenstiel JP, Chen EJ, Bany IA, Mochizuki N, Ashbacher A, Matsuda M, Housman DE, and Graybiel AM. 1998a. A Rap guanine nucleotide exchange factor enriched highly in the basal ganglia. *Proceedings of the National Academy of Sciences of the United States of America* 95:13278-13283.
- Kawasaki H, Springett GM, Mochizuki N, Toki S, Nakaya M, Matsuda M, Housman DE, and Graybiel AM. 1998b. A family of cAMP-binding proteins that directly activate Rap1. *Science* 282:2275-2279.
- Kelly JJ, Barnes PJ, and Giembycz MA. 1996. Phosphodiesterase 4 in macrophages: relationship between cAMP accumulation, suppression of cAMP hydrolysis and inhibition of [<sup>3</sup>H]R(-)-rolipram binding by selective inhibitors. *Biochem J* 318 ( Pt 2):425-436.
- Kenan Y, Murata T, Shakur Y, Degerman E, and Manganiello VC. 2000. Functions of the N-terminal region of cyclic nucleotide phosphodiesterase 3 (PDE 3) isoforms. *J Biol Chem* 275:12331-12338.
- Kerschensteiner M, Stadelmann C, Dechant G, Wekerle H, and Hohlfeld R. 2003. Neurotrophic cross-talk between the nervous and immune systems: implications for neurological diseases. *Ann Neurol* 53:292-304.
- Khoury SJ, Hancock WW, and Weiner HL. 1992. Oral tolerance to myelin basic protein and natural recovery from experimental autoimmune encephalomyelitis are associated with downregulation of inflammatory cytokines and differential upregulation of transforming growth factor beta, interleukin 4, and prostaglandin E expression in the brain. *J Exp Med* 176:1355-1364.
- Kida S, Steart PV, Zhang ET, and Weller RO. 1993. Perivascular cells act as scavengers in the cerebral perivascular spaces and remain distinct from pericytes, microglia and macrophages. *Acta Neuropathol (Berl)* 85:646-652.
- Kiemer AK, Hartung T, and Vollmar AM. 2000. cGMP-mediated inhibition of TNF-alpha production by the atrial natriuretic peptide in murine macrophages. *J Immunol* 165:175-181.
- Kiemer AK and Vollmar AM. 1998. Autocrine regulation of inducible nitric-oxide synthase in macrophages by atrial natriuretic peptide. *J Biol Chem* 273:13444-13451.
- Kihara Y, Ishii S, Kita Y, Toda A, Shimada A, and Shimizu T. 2005. Dual phase regulation of experimental allergic encephalomyelitis by platelet-activating factor. *Journal of Experimental Medicine* 202:853-863.
- Kim NN, Huang YH, Goldstein I, Bischoff E, and Trais AM. 2001. Inhibition of cyclic GMP hydrolysis in human corpus cavernosum smooth muscle cells by vardenafil, a novel, selective phosphodiesterase type 5 inhibitor. *Life Sci* 69:2249-2256.
- Kim YM, Chung HT, Kim SS, Han JA, Yoo YM, Kim KM, Lee GH, Yun HY, Green A, Li J, Simmons RL, and Billiar TR. 1999. Nitric oxide protects PC12 cells from serum deprivation-induced apoptosis by cGMP-dependent inhibition of caspase signaling. *J Neurosci* 19:6740-6747.
- Kincaid RL, Balaban CD, and Billingsley ML. 1992. Regional and developmental expression of calmodulin-dependent cyclic nucleotide phosphodiesterase in rat brain. *Adv Second Messenger Phosphoprotein Res* 25:111-122.
- King CD and Mayer SE. 1974. Inhibition of Egress of Adenosine-3',5'-Monophosphate from Pigeon Erythrocytes. *Molecular Pharmacology* 10:941-953.
- Kingston PA, Zufall F, and Barnstable CJ. 1999. Widespread expression of olfactory cyclic nucleotide-gated channel genes in rat brain: Implications for neuronal signalling. *Synapse* 32:1-12.
- Klussmann E, Maric K, Wiesner B, Beyermann M, and Rosenthal W. 1999. Protein kinase A anchoring proteins are required for vasopressin-mediated translocation of aquaporin-2 into cell membranes of renal principal cells. *J Biol Chem* 274:4934-4938.
- Kobayashi Y, Kawai K, Honda H, Tomida S, Niimi N, Tamatani T, Miyasaka M, and Yoshikai Y. 1995. Antibodies against leukocyte function-associated antigen-1 and against intercellular adhesion molecule-1 together suppress the progression of experimental allergic encephalomyelitis. *Cell Immunol* 164:295-305.
- Kool M, deHaas M, Scheffer GL, Scheper RJ, vanEijk MJT, Juijn JA, Baas F, and Borst P. 1997. Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. *Cancer Research* 57:3537-3547.
- Kotera J, Fujishige K, Akatsuka H, Imai Y, Yanaka N, and Omori K. 1998. Novel alternative splice variants of cGMP-binding cGMP-specific phosphodiesterase. *Journal of Biological Chemistry* 273:26982-26990.
- Kotera J, Fujishige K, Imai Y, Kawai E, Michibata H, Akatsuka H, Yanaka N, and Omori K. 1999a. Genomic origin and transcriptional regulation of two variants of cGMP-binding cGMP-specific phosphodiesterases. *Eur J Biochem* 262:866-873.
- Kotera J, Fujishige K, and Omori K. 2000. Immunohistochemical localization of cGMP-binding cGMP-specific phosphodiesterase (PDE5) in rat tissues. *J Histochem Cytochem* 48:685-693.
- Kotera J, Fujishige K, Yuasa K, and Omori K. 1999b. Characterization and phosphorylation of PDE10A2, a novel alternative splice variant of human phosphodiesterase that hydrolyzes cAMP and cGMP. *Biochem Biophys Res Commun* 261:551-557.
- Kotera J, Grimes KA, Corbin JD, and Francis SH. 2003. CGMP-dependent protein kinase protects cGMP from hydrolysis by phosphodiesterase-5. *Biochemical Journal* 372:419-426.

- Kotera J, Yanaka N, Fujishige K, Imai Y, Akatsuka H, Ishizuka T, Kawashima K, and Omori K. 1997. Expression of rat cGMP-binding cGMP-specific phosphodiesterase mRNA in Purkinje cell layers during postnatal neuronal development. *Eur J Biochem* 249:434-442.
- Kovala T, Sanwal BD, and Ball EH. 1997. Recombinant expression of a type IV, cAMP-specific phosphodiesterase: characterization and structure-function studies of deletion mutants. *Biochemistry* 36:2968-2976.
- Kreutzberg GW. 1996. Microglia: a sensor for pathological events in the CNS. *Trends Neurosci* 19:312-318.
- Kuppenbender KD, Standaert DG, Feuerstein TJ, Penney JB, Jr., Young AB, and Landwehrmeyer GB. 2000. Expression of NMDA receptor subunit mRNAs in neurochemically identified projection and interneurons in the human striatum. *J Comp Neurol* 419:407-421.
- Kuthe A, Magert H, Uckert S, Forssmann WG, Stief CG, and Jonas U. 2000. Gene expression of the phosphodiesterases 3A and 5A in human corpus cavernosum penis. *Eur Urol* 38:108-114.
- Lacroix S, Feinstein D, and Rivest S. 1998. The bacterial endotoxin lipopolysaccharide has the ability to target the brain in upregulating its membrane CD14 receptor within specific cellular populations. *Brain Pathol* 8:625-640.
- Lacroix S and Rivest S. 1998. Effect of acute systemic inflammatory response and cytokines on the transcription of the genes encoding cyclooxygenase enzymes (COX-1 and COX-2) in the rat brain. *J Neurochem* 70:452-466.
- Lagente V, Martin-Chouly C, Boichot E, Martins MA, and Silva PM. 2005. Selective PDE4 inhibitors as potent anti-inflammatory drugs for the treatment of airway diseases. *Mem Inst Oswaldo Cruz* 100 Suppl 1:131-136.
- Lal S, Sharma RK, McGregor C, and Macaulay RJ. 1999. Immunohistochemical localization of calmodulin-dependent cyclic phosphodiesterase in the human brain. *Neurochem Res* 24:43-49.
- Laliberte F, Han Y, Govindarajan A, Giroux A, Liu S, Bobechko B, Lario P, Bartlett A, Gorseth E, Gresser M, and Huang Z. 2000. Conformational difference between PDE4 apoenzyme and holoenzyme. *Biochemistry* 39:6449-6458.
- Lalli E and Sassone-Corsi P. 1994. Signal transduction and gene regulation: the nuclear response to cAMP. *J Biol Chem* 269:17359-17362.
- Lamontagne S, Meadows E, Luk P, Normandin D, Muise E, Boulet L, Pon DJ, Robichaud A, Robertson GS, Metters KM, and Nantel F. 2001. Localization of phosphodiesterase-4 isoforms in the medulla and nodose ganglion of the squirrel monkey. *Brain Res* 920:84-96.
- Lampson LA. 1987. Molecular-Bases of the Immune-Response to Neural Antigens. *Trends in Neurosciences* 10:211-216.
- Lassmann H, Bruck W, and Lucchinetti C. 2001. Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy. *Trends Mol Med* 7:115-121.
- Ledbetter JA, Parsons M, Martin PJ, Hansen JA, Rabinovitch PS, and June CH. 1986. Antibody binding to CD5 (Tp67) and Tp44 T cell surface molecules: effects on cyclic nucleotides, cytoplasmic free calcium, and cAMP-mediated suppression. *J Immunol* 137:3299-3305.
- Lee ME, Markowitz J, Lee JO, and Lee H. 2002. Crystal structure of phosphodiesterase 4D and inhibitor complex(1). *FEBS Lett* 530:53.
- Lehnart SE, Wehrens XH, Reiken S, Warriar S, Belevych AE, Harvey RD, Richter W, Jin SL, Conti M, and Marks AR. 2005. Phosphodiesterase 4D deficiency in the ryanodine-receptor complex promotes heart failure and arrhythmias. *Cell* 123:25-35.
- Lenzlinger PM, Morganti-Kossmann MC, Laurer HL, and McIntosh TK. 2001. The duality of the inflammatory response to traumatic brain injury. *Mol Neurobiol* 24:169-181.
- Lewis GD and Semigran MJ. 2004. Type 5 phosphodiesterase inhibition in heart failure and pulmonary hypertension. *Curr Heart Fail Rep* 1:183-189.
- Lewis TS, Shapiro PS, and Ahn NG. 1998. Signal transduction through MAP kinase cascades. *Adv Cancer Res* 74:49-139.
- Li L, Yee C, and Beavo JA. 1999. CD3- and CD28-dependent induction of PDE7 required for T cell activation. *Science* 283:848-851.
- Liberto CM, Albrecht PJ, Herx LM, Yong VW, and Levison SW. 2004. Pro-regenerative properties of cytokine-activated astrocytes. *J Neurochem* 89:1092-1100.
- Liliental J and Chang DD. 1998. Rack1, a receptor for activated protein kinase C, interacts with integrin beta subunit. *J Biol Chem* 273:2379-2383.
- Lim J, Pahlke G, and Conti M. 1999. Activation of the cAMP-specific phosphodiesterase PDE4D3 by phosphorylation. Identification and function of an inhibitory domain. *J Biol Chem* 274:19677-19685.
- Lin CS, Chow S, Lau A, Tu R, and Lue TF. 2001. Regulation of human PDE5A2 intronic promoter by cAMP and cGMP: identification of a critical Sp1-binding site. *Biochem Biophys Res Commun* 280:693-699.
- Lin CS, Chow S, Lau A, Tu R, and Lue TF. 2002. Human PDE5A gene encodes three PDE5 isoforms from two alternate promoters. *Int J Impot Res* 14:15-24.
- Lin CS, Lau A, Tu R, and Lue TF. 2000. Expression of three isoforms of cGMP-binding cGMP-specific phosphodiesterase (PDE5) in human penile cavernosum. *Biochem Biophys Res Commun* 268:628-635.
- Lincoln TM, Dey N, and Sellak H. 2001. Signal transduction in smooth muscle - Invited review: cGMP-dependent protein kinase signaling mechanisms in smooth muscle: from the regulation of tone to gene expression. *Journal of Applied Physiology* 91:1421-1430.

## Bibliografía

- Lindholm D, Heumann R, Meyer M, and Thoenen H. 1987. Interleukin-1 regulates synthesis of nerve growth factor in non-neuronal cells of rat sciatic nerve. *Nature* 330:658-659.
- Ling EA and Wong WC. 1993. The origin and nature of ramified and amoeboid microglia: a historical review and current concepts. *Glia* 7:9-18.
- Liu H and Maurice DH. 1998. Expression of cyclic GMP-inhibited phosphodiesterases 3A and 3B (PDE3A and PDE3B) in rat tissues: differential subcellular localization and regulated expression by cyclic AMP. *Br J Pharmacol* 125:1501-1510.
- Liu S, Laliberte F, Bobechko B, Bartlett A, Lario P, Gorseth E, Van Hamme J, Gresser MJ, and Huang Z. 2001. Dissecting the cofactor-dependent and independent bindings of pde4 inhibitors. *Biochemistry* 40:10179-10186.
- Liu S, Veilleux A, Zhang L, Young A, Kwok E, Laliberte F, Chung C, Tota MR, Dube D, Friesen RW, and Huang Z. 2005. Dynamic activation of cystic fibrosis transmembrane conductance regulator by type 3 and type 4D phosphodiesterase inhibitors. *J Pharmacol Exp Ther* 314:846-854.
- Livi GP, Kmetz P, McHale MM, Cieslinski LB, Sathe GM, Taylor DP, Davis RL, Torphy TJ, and Balcarek JM. 1990. Cloning and expression of cDNA for a human low-Km, rolipram-sensitive cyclic AMP phosphodiesterase. *Mol Cell Biol* 10:2678-2686.
- Lobban M, Shakur Y, Beattie J, and Houslay MD. 1994. Identification of two splice variant forms of type-IVB cyclic AMP phosphodiesterase, DPD (rPDE-IVB1) and PDE-4 (rPDE-IVB2) in brain: selective localization in membrane and cytosolic compartments and differential expression in various brain regions. *Biochem J* 304 ( Pt 2):399-406.
- Logothetis DE, Kurachi Y, Galper J, Neer EJ, and Clapham DE. 1987. The beta gamma subunits of GTP-binding proteins activate the muscarinic K<sup>+</sup> channel in heart. *Nature* 325:321-326.
- Loughney K, Hill TR, Florio VA, Uher L, Rosman GJ, Wolda SL, Jones BA, Howard ML, McAllister-Lucas LM, Sonnenburg WK, Francis SH, Corbin JD, Beavo JA, and Ferguson K. 1998. Isolation and characterization of cDNAs encoding PDE5A, a human cGMP-binding, cGMP-specific 3',5'-cyclic nucleotide phosphodiesterase. *Gene* 216:139-147.
- Loughney K, Snyder PB, Uher L, Rosman GJ, Ferguson K, and Florio VA. 1999. Isolation and characterization of PDE10A, a novel human 3', 5'-cyclic nucleotide phosphodiesterase. *Gene* 234:109-117.
- Loughney K, Taylor J, and Florio VA. 2005. 3',5'-cyclic nucleotide phosphodiesterase 11A: localization in human tissues. *Int J Impot Res* 17:320-325.
- Lucas KA, Pitari GM, Kazerounian S, Ruiz-Stewart I, Park J, Schulz S, Chepenik KP, and Waldman SA. 2000. Guanylyl cyclases and signaling by cyclic GMP. *Pharmacological Reviews* 52:375-413.
- Lue LF, Brachova L, Civin WH, and Rogers J. 1996. Inflammation, A beta deposition, and neurofibrillary tangle formation as correlates of Alzheimer's disease neurodegeneration. *J Neuropathol Exp Neurol* 55:1083-1088.
- Lugnier C. 2006. Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents. *Pharmacol Ther* 109:366-398.
- Luth HJ, Munch G, and Arendt T. 2002. Aberrant expression of NOS isoforms in Alzheimer's disease is structurally related to nitrotyrosine formation. *Brain Research* 953:135-143.
- Lyman WD, Abrams GA, and Raine CS. 1989. Experimental autoimmune encephalomyelitis: isolation and characterization of inflammatory cells from the central nervous system. *J Neuroimmunol* 25:195-201.
- Lynch MJ, Baillie GS, Mohamed A, Li X, Maisonneuve C, Klussmann E, Van Heeke G, and Houslay MD. 2005. RNA Silencing Identifies PDE4D5 as the Functionally Relevant cAMP Phosphodiesterase Interacting with  $\beta$ Arrestin to Control the Protein Kinase A/AKAP79-mediated Switching of the  $\beta$ 2-Adrenergic Receptor to Activation of ERK in HEK293B2 Cells. *J Biol Chem* 280:33178-33189.
- Lynch MJ, Hill EV, and Houslay MD. 2006. Intracellular targeting of phosphodiesterase-4 underpins compartmentalized cAMP signaling. *Curr Top Dev Biol* 75:225-259.
- Ma D, Wu P, Egan RW, Billah MM, and Wang P. 1999. Phosphodiesterase 4B gene transcription is activated by lipopolysaccharide and inhibited by interleukin-10 in human monocytes. *Mol Pharmacol* 55:50-57.
- MacFarland RT, Zelus BD, and Beavo JA. 1991. High concentrations of a cGMP-stimulated phosphodiesterase mediate ANP-induced decreases in cAMP and steroidogenesis in adrenal glomerulosa cells. *J Biol Chem* 266:136-142.
- MacKenzie SJ, Baillie GS, McPhee I, Bolger GB, and Houslay MD. 2000. ERK2 mitogen-activated protein kinase binding, phosphorylation, and regulation of the PDE4D cAMP-specific phosphodiesterases. THE INVOLVEMENT OF COOH-TERMINAL DOCKING SITES AND NH2-TERMINAL UCR REGIONS. *J Biol Chem* 275:16609-16617.
- MacKenzie SJ, Baillie GS, McPhee I, MacKenzie C, Seamons R, McSorley T, Millen J, Beard MB, Van Heeke G, and Houslay MD. 2002. Long PDE4 cAMP specific phosphodiesterases are activated by protein kinase A-mediated phosphorylation of a single serine residue in Upstream Conserved Region 1 (UCR1). *Br J Pharmacol* 136:421-433.
- MacKenzie SJ, Yarwood SJ, Peden AH, Bolger GB, Vernon RG, and Houslay MD. 1998. Stimulation of p70S6 kinase via a growth hormone-controlled phosphatidylinositol 3-kinase pathway leads to the activation of a

- PDE4A cyclic AMP-specific phosphodiesterase in 3T3-F442A preadipocytes. *Proc Natl Acad Sci U S A* 95:3549-3554.
- Macphee CH, Harrison SA, and Beavo JA. 1986. Immunological identification of the major platelet low-Km cAMP phosphodiesterase: probable target for anti-thrombotic agents. *Proc Natl Acad Sci U S A* 83:6660-6663.
- Male D, Rahman J, Pryce G, Tamatani T, and Miyasaka M. 1994. Lymphocyte migration into the CNS modelled in vitro: roles of LFA-1, ICAM-1 and VLA-4. *Immunology* 81:366-372.
- Manganiello VC, Murata T, Taira M, Belfrage P, and Degerman E. 1995a. Diversity in cyclic nucleotide phosphodiesterase isoenzyme families. *Arch Biochem Biophys* 322:1-13.
- Manganiello VC, Taira M, Degerman E, and Belfrage P. 1995b. Type III cGMP-inhibited cyclic nucleotide phosphodiesterases (PDE3 gene family). *Cell Signal* 7:445-455.
- Manning CD, Burman M, Christensen SB, Cieslinski LB, Essayan DM, Grous M, Torphy TJ, and Barnette MS. 1999. Suppression of human inflammatory cell function by subtype-selective PDE4 inhibitors correlates with inhibition of PDE4A and PDE4B. *Br J Pharmacol* 128:1393-1398.
- Marchmont RJ, Ayad SR, and Houslay MD. 1981. Purification and properties of the insulin-stimulated cyclic AMP phosphodiesterase from rat liver plasma membranes. *Biochem J* 195:645-652.
- Marchmont RJ and Houslay MD. 1980. A peripheral and an intrinsic enzyme constitute the cyclic AMP phosphodiesterase activity of rat liver plasma membranes. *Biochem J* 187:381-392.
- Marcoz P, Nemoz G, Prigent AF, and Lagarde M. 1993. Phosphatidic acid stimulates the rolipram-sensitive cyclic nucleotide phosphodiesterase from rat thymocytes. *Biochim Biophys Acta* 1176:129-136.
- Marinissen MJ and Gutkind JS. 2001. G-protein-coupled receptors and signaling networks: emerging paradigms. *Trends Pharmacol Sci* 22:368-376.
- Marjamaki A, Sato M, BouetAlard R, Yang Q, LimonBoulez I, Legrand C, and Lanier SM. 1997. Factors determining the specificity of signal transduction by guanine nucleotide-binding protein-coupled receptors - Integration of stimulatory and inhibitory input to the effector adenyl cyclase. *Journal of Biological Chemistry* 272:16466-16473.
- Marko D, Romanakis K, Zankl H, Furstenberger G, Steinbauer B, and Eisenbrand G. 1998. Induction of apoptosis by an inhibitor of cAMP-specific PDE in malignant murine carcinoma cells overexpressing PDE activity in comparison to their nonmalignant counterparts. *Cell Biochem Biophys* 28:75-101.
- Marques F, Sousa JC, Correia-Neves M, Oliveira P, Sousa N, and Palha JA. 2007. The choroid plexus response to peripheral inflammatory stimulus. *Neuroscience* 144:424-430.
- Martin-Padura I, Lostaglio S, Schneemann M, Williams L, Romano M, Fruscella P, Panzeri C, Stoppacciaro A, Ruco L, Villa A, Simmons D, and Dejana E. 1998. Junctional adhesion molecule, a novel member of the immunoglobulin superfamily that distributes at intercellular junctions and modulates monocyte transmigration. *J Cell Biol* 142:117-127.
- Martínez A, Castro A, Gil C, Miralpeix M, Segarra V, Domènech T, Beleta J, Palacios JM, Ryder H, Miró X, Bonet C, Casacuberta JM, Azorin F, Pina B, and Puigdomènech P. 2000. Benzyl derivatives of 2,1,3-benzo- and benzothieno[3,2-a]thiadiazine 2,2-dioxides: first phosphodiesterase 7 inhibitors. *J Med Chem* 43:683-689.
- Martinez I, Puerta C, Redondo C, and Garcia-Merino A. 1999a. Type IV phosphodiesterase inhibition in experimental allergic encephalomyelitis of Lewis rats: sequential gene expression analysis of cytokines, adhesion molecules and the inducible nitric oxide synthase. *J Neurol Sci* 164:13-23.
- Martinez M, Fernandez E, Frank A, Guaza C, de la Fuente M, and Hernanz A. 1999b. Increased cerebrospinal fluid cAMP levels in Alzheimer's disease. *Brain Res* 846:265-267.
- Martinez SE, Wu AY, Glavas NA, Tang XB, Turley S, Hol WGJ, and Beavo JA. 2002. The two GAF domains in phosphodiesterase 2A have distinct roles in dimerization and in cGMP binding. *Proceedings of the National Academy of Sciences of the United States of America* 99:13260-13265.
- Mata M, Sarria B, Buenestado A, Cortijo J, Cerda M, and Morcillo EJ. 2005. Phosphodiesterase 4 inhibition decreases MUC5AC expression induced by epidermal growth factor in human airway epithelial cells. *Thorax* 60:144-152.
- Mato M, Ookawara S, Sakamoto A, Aikawa E, Ogawa T, Mitsuhashi U, Masuzawa T, Suzuki H, Honda M, Yazaki Y, Watanabe E, Luoma J, Yla-Herttuala S, Fraser I, Gordon S, and Kodama T. 1996. Involvement of specific macrophage-lineage cells surrounding arterioles in barrier and scavenger function in brain cortex. *Proc Natl Acad Sci U S A* 93:3269-3274.
- Matsuda M, Tsukada N, Miyagi K, and Yanagisawa N. 1995. Adhesion of Lymphocytes to Endothelial-Cells in Experimental Allergic Encephalomyelitis Before and After Treatment with Endotoxin Lipopolysaccharide. *International Archives of Allergy and Immunology* 106:335-344.
- Maurice DH. 2005. Cyclic nucleotide phosphodiesterase-mediated integration of cGMP and cAMP signaling in cells of the cardiovascular system. *Front Biosci* 10:1221-1228.
- Mayr B and Montminy M. 2001. Transcriptional regulation by the phosphorylation-dependent factor CREB. *Nat Rev Mol Cell Biol* 2:599-609.
- McAleer MA, Breen MA, White NL, and Matthews N. 1999. PABC11 (also known as MOAT-C

- and MRP5), a member of the ABC family of proteins, has anion transporter activity but does not confer multidrug resistance when overexpressed in human embryonic kidney 293 cells. *Journal of Biological Chemistry* 274:23541-23548.
- McAllister-Lucas LM, Sonnenburg WK, Kadlec A, Seger D, Trong HL, Colbran JL, Thomas MK, Walsh KA, Francis SH, Corbin JD, and . 1993. The structure of a bovine lung cGMP-binding, cGMP-specific phosphodiesterase deduced from a cDNA clone. *J Biol Chem* 268:22863-22873.
- McCahill A, McSorley T, Huston E, Hill EV, Lynch MJ, Gall I, Keryer G, Lygren B, Tasken K, Van Heeke G, and Houslay MD. 2005. In resting COS1 cells a dominant negative approach shows that specific, anchored PDE4 cAMP phosphodiesterase isoforms gate the activation, by basal cyclic AMP production, of AKAP-tethered protein kinase A type II located in the centrosomal region. *Cell Signal* 17:1158-1173.
- McCahill A, Warwicker J, Bolger GB, Houslay MD, and Yarwood SJ. 2002. The RACK1 scaffold protein: a dynamic cog in cell response mechanisms. *Mol Pharmacol* 62:1261-1273.
- McGeer PL, McGeer E, Rogers J, and Sibley J. 1990. Anti-inflammatory drugs and Alzheimer disease [letter] [see comments]. *Lancet* 335:1037.
- McGeer PL and McGeer EG. 1995. The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases. *Brain Res Rev* 21:195-218.
- McGeer PL and McGeer EG. 2001. Inflammation, autotoxicity and Alzheimer disease. *Neurobiol Aging* 22:799-809.
- McLaughlin ME, Sandberg MA, Berson EL, and Dryja TP. 1993a. Recessive mutations in the gene encoding the beta-subunit of rod phosphodiesterase in patients with retinitis pigmentosa. *Nat Genet* 4:130-134.
- McLaughlin MM, Cieslinski LB, Burman M, Torphy TJ, and Livi GP. 1993b. A low-Km, rolipram-sensitive, cAMP-specific phosphodiesterase from human brain. Cloning and expression of cDNA, biochemical characterization of recombinant protein, and tissue distribution of mRNA. *J Biol Chem* 268:6470-6476.
- McPhee I, Yarwood SJ, Scotland G, Huston E, Beard MB, Ross AH, Houslay ES, and Houslay MD. 1999. Association with the SRC family tyrosyl kinase LYN triggers a conformational change in the catalytic region of human cAMP-specific phosphodiesterase HSPDE4A4B. Consequences for rolipram inhibition. *J Biol Chem* 274:11796-11810.
- Mehats C, Jin SL, Wahlstrom J, Law E, Umetsu DT, and Conti M. 2003. PDE4D plays a critical role in the control of airway smooth muscle contraction. *FASEB J* 17:1831-1841.
- Mennicken F, Maki R, De Souza EB, and Quirion R. 1999. Chemokines and chemokine receptors in the CNS: a possible role in neuroinflammation and patterning. *Trends Pharmacol Sci* 20:73-78.
- Mergia E, Russwurm M, Zoidl G, and Koesling D. 2003. Major occurrence of the new alpha2beta1 isoform of NO-sensitive guanylyl cyclase in brain. *Cell Signal* 15:189-195.
- Mery PF, Pavoine C, Pecker F, and Fischmeister R. 1995. Erythro-9-(2-hydroxy-3-nonyl)adenine inhibits cyclic GMP-stimulated phosphodiesterase in isolated cardiac myocytes. *Mol Pharmacol* 48:121-130.
- Mhaouty S, Cohentannoudji J, BouetAlard R, LimonBoulez I, Maltier JP, and Legrand C. 1995. Characteristics of the Alpha(2)/Beta(2)-Adrenergic Receptor-Coupled Adenylyl-Cyclase System in Rat Myometrium During Pregnancy. *Journal of Biological Chemistry* 270:11012-11016.
- Michaeli T, Bloom TJ, Martins T, Loughney K, Ferguson K, Riggs M, Rodgers L, Beavo JA, and Wigler M. 1993. Isolation and characterization of a previously undetected human cAMP phosphodiesterase by complementation of cAMP phosphodiesterase-deficient *Saccharomyces cerevisiae*. *J Biol Chem* 268:12925-12932.
- Michel JJ and Scott JD. 2002. AKAP mediated signal transduction. *Annu Rev Pharmacol Toxicol* 42:235-257.
- Michie AM, Lobban M, Muller T, Harnett MM, and Houslay MD. 1996. Rapid regulation of PDE-2 and PDE-4 cyclic AMP phosphodiesterase activity following ligation of the T cell antigen receptor on thymocytes: analysis using the selective inhibitors erythro-9-(2-hydroxy-3-nonyl)-adenine (EHNA) and rolipram. *Cell Signal* 8:97-110.
- Middendorff R, Davidoff MS, Behrends S, Mewe M, Miethens A, and Muller D. 2000. Multiple roles of the messenger molecule cGMP in testicular function. *Andrologia* 32:55-59.
- Milatovich A, Bolger G, Michaeli T, and Francke U. 1994. Chromosome localizations of genes for five cAMP-specific phosphodiesterases in man and mouse. *Somat Cell Mol Genet* 20:75-86.
- Millar JK, James R, Brandon NJ, and Thomson PA. 2004. DISC1 and DISC2: discovering and dissecting molecular mechanisms underlying psychiatric illness. *Ann Med* 36:367-378.
- Millar JK, Pickard BS, Mackie S, James R, Christie S, Buchanan SR, Malloy MP, Chubb JE, Huston E, Baillie GS, Thomson PA, Hill EV, Brandon NJ, Rain JC, Camargo LM, Whiting PJ, Houslay MD, Blackwood DH, Muir WJ, and Porteous DJ. 2005. DISC1 and PDE4B are interacting genetic factors in schizophrenia that regulate cAMP signaling. *Science* 310:1187-1191.
- Millhouse OE. 1987. Granule cells of the olfactory tubercle and the question of the islands of Calleja. *J Comp Neurol* 265:1-24.
- Miró X, Pérez-Torres S, Artigas F, Puigdomènech P, Palacios JM, and Mengod G. 2002a. Regulation of cAMP phosphodiesterase mRNAs expression in rat brain by acute and

- chronic fluoxetine treatment. An in situ hybridization study. *Neuropharmacology* 43:1148-1157.
- Miró X, Pérez-Torres S, Palacios JM, Puigdomènech P, and Mengod G. 2001. Differential distribution of cAMP-specific phosphodiesterase 7A mRNA in rat brain and peripheral organs. *Synapse* 40:201-214.
- Miró X, Pérez-Torres S, Puigdomènech P, Palacios JM, and Mengod G. 2002b. Differential distribution of PDE4D splice variant mRNAs in rat brain suggests association with specific pathways and presynaptic localization. *Synapse* 45:259-269.
- Mo E, Amin H, Bianco IH, and Garthwaite J. 2004. Kinetics of a cellular nitric oxide/cGMP/phosphodiesterase-5 pathway. *J Biol Chem* 279:26149-26158.
- Mochly-Rosen D, Smith BL, Chen CH, Disatnik MH, and Ron D. 1995. Interaction of protein kinase C with RACK1, a receptor for activated C-kinase: a role in beta protein kinase C mediated signal transduction. *Biochem Soc Trans* 23:596-600.
- Moncada S, Palmer RM, and Higgs EA. 1991. Nitric oxide: physiology, pathophysiology, and pharmacology. *Pharmacol Rev* 43:109-142.
- Montero-Menei CN, Sindji L, Garcion E, Mege M, Couez D, Gamelin E, and Darcy F. 1996. Early events of the inflammatory reaction induced in rat brain by lipopolysaccharide intracerebral injection: relative contribution of peripheral monocytes and activated microglia. *Brain Res* 724:55-66.
- Montero-Menei CN, Sindji L, Pouplard-Barthelaix A, Jehan F, Denechaud L, and Darcy F. 1994. Lipopolysaccharide intracerebral administration induces minimal inflammatory reaction in rat brain. *Brain Res* 653:101-111.
- Montixi C, Langlet C, Bernard AM, Thimonier J, Dubois C, Wurbel MA, Chauvin JP, Pierres M, and He HT. 1998. Engagement of T cell receptor triggers its recruitment to low-density detergent-insoluble membrane domains. *EMBO J* 17:5334-5348.
- Montorsi F, Corbin J, and Phillips S. 2004. Review of phosphodiesterases in the urogenital system: new directions for therapeutic intervention. *J Sex Med* 1:322-336.
- Moore AR and Willoughby DA. 1995. The Role of Camp Regulation in Controlling Inflammation. *Clinical and Experimental Immunology* 101:387-389.
- Moore CS, Earl N, Frenette R, Styhler A, Mancini JA, Nicholson DW, Hebb AL, Owens T, and Robertson GS. 2006. Peripheral phosphodiesterase 4 inhibition produced by 4-[2-(3,4-Bis-difluoromethoxyphenyl)-2-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropyl)-phenyl]-ethyl]-3-methylpyridine-1-oxide (L-826,141) prevents experimental autoimmune encephalomyelitis. *J Pharmacol Exp Ther* 319:63-72.
- Morandini R, Ghanem G, Portier-Lemarie A, Robaye B, Renaud A, and Boeynaems JM. 1996. Action of cAMP on expression and release of adhesion molecules in human endothelial cells. *Am J Physiol* 270:H807-H816.
- Morimoto BH and Koshland DEJ. 1991. Identification of cyclic AMP as the response regulator for neurosecretory potentiation: a memory model system. *Proc Natl Acad Sci U S A* 88:10835-10839.
- Morini M, Roccatagliata L, Dell'Eva R, Pedemonte E, Furlan R, Minghelli S, Giunti D, Pfeffer U, Marchese M, Noonan D, Mancardi G, Albin A, and Uccelli A. 2004. alpha-Lipoic acid is effective in prevention and treatment of experimental autoimmune encephalomyelitis. *Journal of Neuroimmunology* 148:146-153.
- Morrissey SP, Deichmann R, Syha J, Simonis C, Zettl U, Archelos JJ, Jung S, Stodal H, Lassmann H, Toyka KV, Haase A, and Hartung HP. 1996. Partial inhibition of AT-EAE by an antibody to ICAM-1: clinico-histological and MRI studies. *J Neuroimmunol* 69:85-93.
- Mseeh F, Colman RF, and Colman RW. 2000. Inactivation of platelet PDE2 by an affinity label: 8-[(4-bromo-2, 3-dioxobutyl)thio]cAMP. *Thromb Res* 98:395-401.
- Muller DM, Pender MP, and Greer JM. 2004. Chemokines and chemokine receptors: potential therapeutic targets in multiple sclerosis. *Curr Drug Targets Inflamm Allergy* 3:279-290.
- Muller T, Engels P, and Fozard JR. 1996. Subtypes of the type 4 cAMP phosphodiesterases: structure, regulation and selective inhibition. *Trends Pharmacol Sci* 17:294-298.
- Murad F. 1998. Nitric oxide signaling: would you believe that a simple free radical could be a second messenger, autacoid, paracrine substance, neurotransmitter, and hormone? *Recent Prog Horm Res* 53:43-59.
- Muradov KG, Granovsky AE, and Artemyev NO. 2003. Mutation in rod PDE6 linked to congenital stationary night blindness impairs the enzyme inhibition by its gamma-subunit. *Biochemistry* 42:3305-3310.
- Murakami M and Kudo I. 2004. Recent advances in molecular biology and physiology of the prostaglandin E2-biosynthetic pathway. *Prog Lipid Res* 43:3-35.
- Murata T, Sugatani T, Shimizu K, Manganiello VC, and Tagawa T. 2001. Phosphodiesterase 3 as a potential target for therapy of malignant tumors in the submandibular gland. *Anticancer Drugs* 12:79-83.
- Murata T, Sugatani T, and Tagawa T. 2000. Expression of phosphodiesterase 3 in rat submandibular gland. *Arch Oral Biol* 45:1043-1047.
- Murthy KS, Zhou HP, and Makhlof GM. 2002. PKA-dependent activation of PDE3A and PDE4 and inhibition of adenylyl cyclase V/VI in smooth muscle. *American Journal of Physiology-Cell Physiology* 282:C508-C517.
- Nadeau S and Rivest S. 1999. Regulation of the gene encoding tumor necrosis factor alpha (TNF-alpha) in the rat brain and pituitary in

- response in different models of systemic immune challenge. *J Neuropathol Exp Neurol* 58:61-77.
- Nagakura A, Niimura M, and Takeo S. 2002. Effects of a phosphodiesterase IV inhibitor rolipram on microsphere embolism-induced defects in memory function and cerebral cyclic AMP signal transduction system in rats. *Br J Pharmacol* 135:1783-1793.
- Nakajima K and Kohsaka S. 1993. Functional roles of microglia in the brain. *Neurosci Res* 17:187-203.
- Nakata A, Ogawa K, Sasaki T, Koyama N, Wada K, Kotera J, Kikkawa H, Omori K, and Kaminuma O. 2002. Potential role of phosphodiesterase 7 in human T cell function: comparative effects of two phosphodiesterase inhibitors. *Clin Exp Immunol* 128:460-466.
- Naro F, Sette C, Vicini E, De A, V, Grange M, Conti M, Lagarde M, Molinaro M, Adamo S, and Nemoz G. 1999. Involvement of type 4 cAMP-phosphodiesterase in the myogenic differentiation of L6 cells. *Mol Biol Cell* 10:4355-4367.
- Nemoz G, Sette C, and Conti M. 1997. Selective activation of rolipram-sensitive, cAMP-specific phosphodiesterase isoforms by phosphatidic acid. *Mol Pharmacol* 51:242-249.
- Netherton SJ and Maurice DH. 2005. Vascular endothelial cell cyclic nucleotide phosphodiesterases and regulated cell migration: implications in angiogenesis. *Mol Pharmacol* 67:263-272.
- Neumann H. 2000. The immunological microenvironment in the CNS: implications on neuronal cell death and survival. *J Neural Transm Suppl* 59:59-68.
- Neumann H, Cavalie A, Jenne DE, and Wekerle H. 1995. Induction of MHC class I genes in neurons. *Science* 269:549-552.
- Neumann H, Schmidt H, Cavalie A, Jenne D, and Wekerle H. 1997. Major histocompatibility complex (MHC) class I gene expression in single neurons of the central nervous system: differential regulation by interferon (IFN)-gamma and tumor necrosis factor (TNF)-alpha. *J Exp Med* 185:305-316.
- Neumann H, Schweigreiter R, Yamashita T, Rosenkranz K, Wekerle H, and Barde YA. 2002. Tumor necrosis factor inhibits neurite outgrowth and branching of hippocampal neurons by a rho-dependent mechanism. *J Neurosci* 22:854-862.
- Nikulina E, Tidwell JL, Dai HN, Bregman BS, and Filbin MT. 2004. The phosphodiesterase inhibitor rolipram delivered after a spinal cord lesion promotes axonal regeneration and functional recovery. *Proc Natl Acad Sci U S A* 101:8786-8790.
- Nishi T, Kimura Y, and Nakagawa K. 2000. [Research and development of cilostazol: an antiplatelet agent]. *Yakugaku Zasshi* 120:1247-1260.
- Norenberg MD. 1994. Astrocyte responses to CNS injury. *J Neuropathol Exp Neurol* 53:213-220.
- Norton AW, Hosier S, Terew JM, Li N, Dhingra A, Vardi N, Baehr W, and Cote RH. 2005. Evaluation of the 17-kDa prenyl-binding protein as a regulatory protein for phototransduction in retinal photoreceptors. *J Biol Chem* 280:1248-1256.
- Norton WT, Aquino DA, Hozumi I, Chiu FC, and Brosnan CF. 1992. Quantitative aspects of reactive gliosis: a review. *Neurochem Res* 17:877-885.
- O'Brien J. 2003. Behavioral symptoms in vascular cognitive impairment and vascular dementia. *Int Psychogeriatr* 15 Suppl 1:133-138.
- O'Connell JC, McCallum JF, McPhee I, Wakefield J, Houslay ES, Wishart W, Bolger G, Frame M, and Houslay MD. 1996. The SH3 domain of Src tyrosyl protein kinase interacts with the N-terminal splice region of the PDE4A cAMP-specific phosphodiesterase RPDE-6 (RNPDE4A5). *Biochem J* 318 ( Pt 1):255-261.
- O'Connor V, Genin A, Davis S, Karishma KK, Doyere V, De Zeeuw CI, Sanger G, Hunt SP, Richter-Levin G, Mallet J, Laroche S, Bliss TV, and French PJ. 2004. Differential amplification of intron-containing transcripts reveals long term potentiation-associated up-regulation of specific Pde10A phosphodiesterase splice variants. *J Biol Chem* 279:15841-15849.
- O'Donnell JM and Zhang HT. 2004a. Antidepressant effects of inhibitors of cAMP phosphodiesterase (PDE4). *Trends Pharmacol Sci* 25:158-163.
- O'Donnell JM and Zhang HT. 2004b. Antidepressant effects of inhibitors of cAMP phosphodiesterase (PDE4). *Trends Pharmacol Sci* 25:158-163.
- Oberholte R, Ratzliff J, Baecker PA, Daniels DV, Zuppan P, Jarnagin K, and Shelton ER. 1997. Multiple splice variants of phosphodiesterase PDE4C cloned from human lung and testis. *Biochim Biophys Acta* 1353:287-297.
- Ogawa R, Streiff MB, Bugayenko A, and Kato GJ. 2002. Inhibition of PDE4 phosphodiesterase activity induces growth suppression, apoptosis, glucocorticoid sensitivity, p53, and p21(WAF1/CIP1) proteins in human acute lymphoblastic leukemia cells. *Blood* 99:3390-3397.
- Ohm TG, Schmitt M, Bohl J, and Lemmer B. 1997. Decrease in adenylate cyclase activity antecedes neurofibrillary tangle formation. *Neurobiol Aging* 18:275-279.
- Oki N, Takahashi SI, Hidaka H, and Conti M. 2000. Short term feedback regulation of cAMP in FRTL-5 thyroid cells. Role of PDE4D3 phosphodiesterase activation. *J Biol Chem* 275:10831-10837.
- Ollivier V, Parry GCN, Cobb RR, de Prost D, and Mackman N. 1996. Elevated cyclic AMP inhibits NF-kappaB-mediated transcription in human monocytic cells and endothelial cells. *J Biol Chem* 271:20828-20835.
- Omburo GA, Jacobitz S, Torphy TJ, and Colman RW. 1998. Critical role of conserved histidine pairs HNXXH and HDXXH in recombinant

- human phosphodiesterase 4A. *Cell Signal* 10:491-497.
- Osborn L. 1990. Leukocyte adhesion to endothelium in inflammation. *Cell* 62:3-6.
- Otmakhov N, Khibnik L, Otmakhova N, Carpenter S, Riahi S, Asrican B, and Lisman J. 2004. Forskolin-induced LTP in the CA1 hippocampal region is NMDA receptor dependent. *J Neurophysiol* 91:1955-1962.
- Owens RJ, Catterall C, Batty D, Jappy J, Russell A, Smith B, O'Connell J, and Perry MJ. 1997. Human phosphodiesterase 4A: characterization of full-length and truncated enzymes expressed in COS cells. *Biochem J* 326 ( Pt 1):53-60.
- Palm D, Wiemer G, and Dietz J. 1981. Efflux of 3',5'-Camp from Immature Rat Erythrocytes - Dependence on Intracellular Concentrations of Camp and Atp. *Naunyn-Schmiedebergs Archives of Pharmacology* 317:372.
- Palmer AM. 2002. Pharmacotherapy for Alzheimer's disease: progress and prospects. *Trends Pharmacol Sci* 23:426-433.
- Paris D, Town T, Parker TA, Tan J, Humphrey J, Crawford F, and Mullan M. 1999. Inhibition of Alzheimer's beta-amyloid induced vasoactivity and proinflammatory response in microglia by a cGMP-dependent mechanism. *Exp Neurol* 157:211-221.
- Parkes JD, Thompson C, Brennan L, Gajraj N, Howcroft B, and Ruiz J. 1984. Rolipram in Parkinson's disease. *Adv Neurol* 40:563-565.
- Parma J, Duprez L, Vansande J, Cochaux P, Gervy C, Mockel J, Dumont J, and Vassart G. 1993. Somatic Mutations in the Thyrotropin Receptor Gene Cause Hyperfunctioning Thyroid Adenomas. *Nature* 365:649-651.
- Parsian A, Todd RD, Cloninger CR, Hoffman PL, Ovchinnikova L, Ikeda H, Tabakoff B, Schuckit MA, Rappaport M, Tsuang J, Salaspuro M, Monteiro MG, Balant LP, Davidson C, Ogata M, Yamashita I, and Grant BF. 1996. Platelet adenylyl cyclase activity in alcoholics and subtypes of alcoholics. *Alcoholism-Clinical and Experimental Research* 20:745-751.
- Pashenkov M, Teleshova N, Kouwenhoven M, Smirnova T, Jin YP, Kostulas V, Huang YM, Pinegin B, Boiko A, and Link H. 2002. Recruitment of dendritic cells to the cerebrospinal fluid in bacterial neuroinfections. *J Neuroimmunol* 122:106-116.
- Paxinos G and Watson C. 1998. *The Rat Brain in stereotaxic coordinates*. San Diego: Academic Press.
- Pérez-Torres S, Cortés R, Tolnay M, Probst A, Palacios JM, and Mengod G. 2003. Alterations on phosphodiesterase type 7 and 8 isozyme mRNA expression in Alzheimer's disease brains examined by *in situ* hybridization. *Exp Neurol* 182:322-334.
- Pérez-Torres S and Mengod G. 2002. cAMP-specific phosphodiesterases expression in Alzheimer's disease brains. In Satoh K, Suzuki S, and Matsunaga M, editors. *Advances in Brain Research*. Amsterdam: Elsevier Science B.V. p 127-138.
- Pérez-Torres S, Miró X, Palacios JM, Cortés R, Puigdomènech P, and Mengod G. 2000. Phosphodiesterase type 4 isozymes expression in human brain examined by *in situ* hybridization histochemistry and [<sup>3</sup>H]rolipram binding autoradiography. Comparison with monkey and rat brain. *J Chem Neuroanat* 20:349-374.
- Perry VH, Anthony DC, Bolton SJ, and Brown HC. 1997. The blood-brain barrier and the inflammatory response. *Mol Med Today* 3:335-341.
- Perry VH, Bell MD, Brown HC, and Matyszak MK. 1995. Inflammation in the Nervous-System. *Current Opinion in Neurobiology* 5:636-641.
- Perry VH and Gordon S. 1991. Macrophages and the nervous system. *Int Rev Cytol* 125:203-244.
- Pian MS and Dobbs LG. 1995. Evidence for G-Beta-Gamma-Mediated Cross-Talk in Primary Cultures of Lung Alveolar Cells. *Journal of Biological Chemistry* 270:7427-7430.
- Pierce KL, Premont RT, and Lefkowitz RJ. 2002. Seven-transmembrane receptors. *Nat Rev Mol Cell Biol* 3:639-650.
- Pifarre P, Garcia A, and Mengod G. 2007. Species differences in the localization of soluble guanylyl cyclase subunits in monkey and rat brain. *J Comp Neurol* 500:942-957.
- Pilewski JM and Frizzell RA. 1999. Role of CFTR in airway disease. *Physiol Rev* 79:S215-S255.
- Platzer C, Fritsch E, Elsner T, Lehmann MH, Volk HD, and Prosch S. 1999. Cyclic adenosine monophosphate-responsive elements are involved in the transcriptional activation of the human IL-10 gene in monocytic cells. *Eur J Immunol* 29:3098-3104.
- Pober JS, Slowik MR, De Luca LG, and Ritchie AJ. 1993. Elevated cyclic AMP inhibits endothelial cell synthesis and expression of TNF-induced endothelial leukocyte adhesion molecule-1, and vascular cell adhesion molecule-1, but not intercellular adhesion molecule-1. *J Immunol* 150:5114-5123.
- Polfliet MM, van d, V, Dopp EA, Kesteren-Hendriks EM, Van Rooijen N, Dijkstra CD, and van den Berg TK. 2002. The role of perivascular and meningeal macrophages in experimental allergic encephalomyelitis. *J Neuroimmunol* 122:1-8.
- Polli JW and Kincaid RL. 1994. Expression of a calmodulin-dependent phosphodiesterase isoform (PDE1B1) correlates with brain regions having extensive dopaminergic innervation. *J Neurosci* 14:1251-1261.
- Polman CH, Dijkstra CD, Sminia T, and Koetsier JC. 1986. Immunohistological analysis of macrophages in the central nervous system of Lewis rats with acute experimental allergic encephalomyelitis. *J Neuroimmunol* 11:215-222.
- Pomeroy IM, Matthews PM, Frank JA, Jordan EK, and Esiri MM. 2005. Demyelinated neocortical lesions in marmoset autoimmune encephalomyelitis mimic those in multiple sclerosis. *Brain* 128:2713-2721.



## Bibliografía

- Porter AG and Janicke RU. 1999. Emerging roles of caspase-3 in apoptosis. *Cell Death and Differentiation* 6:99-104.
- Pouyssegur J and Lenormand P. 2003. Fidelity and spatio-temporal control in MAP kinase (ERKs) signalling. *Eur J Biochem* 270:3291-3299.
- Prickaerts J, Koopmans G, Blokland A, and Scheepens A. 2004a. Learning and adult neurogenesis: survival with or without proliferation? *Neurobiol Learn Mem* 81:1-11.
- Prickaerts J, Sik A, van Staveren WC, Koopmans G, Steinbusch HW, van der Staay FJ, de Vente J, and Blokland A. 2004b. Phosphodiesterase type 5 inhibition improves early memory consolidation of object information. *Neurochem Int* 45:915-928.
- Pryce G, Male D, Campbell I, and Greenwood J. 1997. Factors controlling T-cell migration across rat cerebral endothelium in vitro. *J Neuroimmunol* 75:84-94.
- Pyne NJ and Furman BL. 2003. Cyclic nucleotide phosphodiesterases in pancreatic islets. *Diabetologia* 46:1179-1189.
- Quan N, Stern EL, Whiteside MB, and Herkenham M. 1999. Induction of pro-inflammatory cytokine mRNAs in the brain after peripheral injection of subseptic doses of lipopolysaccharide in the rat. *J Neuroimmunol* 93:72-80.
- Quan N, Whiteside M, and Herkenham M. 1998. Cyclooxygenase 2 mRNA expression in rat brain after peripheral injection of lipopolysaccharide. *Brain Res* 802:189-197.
- Quan N, Whiteside M, Kim L, and Herkenham M. 1997. Induction of inhibitory factor kappaB $\alpha$  mRNA in the central nervous system after peripheral lipopolysaccharide administration: an in situ hybridization histochemistry study in the rat. *Proc Natl Acad Sci U S A* 94:10985-10990.
- RALL TW, Sutherland EW, and WOSILAIT WD. 1956. The relationship of epinephrine and glucagon to liver phosphorylase. III. Reactivation of liver phosphorylase in slices and in extracts. *J Biol Chem* 218:483-495.
- Ramos BP, Birnbaum SG, Lindenmayer I, Newton SS, Duman RS, and Arnsten AF. 2003. Dysregulation of protein kinase a signaling in the aged prefrontal cortex: new strategy for treating age-related cognitive decline. *Neuron* 40:835-845.
- Ransohoff RM. 2002. Chemokines in neurological trauma models. *Ann N Y Acad Sci* 961:346-349.
- Ransohoff RM, Kivisakk P, and Kidd G. 2003. Three or more routes for leukocyte migration into the central nervous system. *Nat Rev Immunol* 3:569-581.
- Reeves ML, Leigh BK, and England PJ. 1987. The identification of a new cyclic nucleotide phosphodiesterase activity in human and guinea-pig cardiac ventricle. Implications for the mechanism of action of selective phosphodiesterase inhibitors. *Biochem J* 241:535-541.
- Reinhardt RR and Bondy CA. 1996. Differential cellular pattern of gene expression for two distinct cGMP-inhibited cyclic nucleotide phosphodiesterases in developing and mature rat brain. *Neuroscience* 72:567-578.
- Reinhardt RR, Chin E, Zhou J, Taira M, Murata T, Manganiello VC, and Bondy CA. 1995. Distinctive anatomical patterns of gene expression for cGMP-inhibited cyclic nucleotide phosphodiesterases. *J Clin Invest* 95:1528-1538.
- Rentero C, Monfort A, and Puigdomènech P. 2003. Identification and distribution of different mRNA variants produced by differential splicing in the human phosphodiesterase 9A gene. *Biochem Biophys Res Commun* 301:686-692.
- Repaske DR, Corbin JG, Conti M, and Goy MF. 1993. A cyclic GMP-stimulated cyclic nucleotide phosphodiesterase gene is highly expressed in the limbic system of the rat brain. *Neuroscience* 56:673-686.
- Rich TC, Fagan KA, Tse TE, Schaack J, Cooper DM, and Karpen JW. 2001. A uniform extracellular stimulus triggers distinct cAMP signals in different compartments of a simple cell. *Proc Natl Acad Sci U S A* 98:13049-13054.
- Richard FJ, Tsafriri A, and Conti M. 2001. Role of phosphodiesterase type 3A in rat oocyte maturation. *Biol Reprod* 65:1444-1451.
- Richter W. 2002. 3',5'-cyclic nucleotide phosphodiesterases class III: Members, structure, and catalytic mechanism. *Proteins-Structure Function and Genetics* 46:278-286.
- Richter W and Conti M. 2002. Dimerization of the type 4 cAMP-specific phosphodiesterases is mediated by the upstream conserved regions (UCRs). *Journal of Biological Chemistry* 277:40212-40221.
- Richter W and Conti M. 2004. The oligomerization state determines regulatory properties and inhibitor sensitivity of type 4 cAMP-specific phosphodiesterases. *J Biol Chem* 279:30338-30348.
- Risau W, Engelhardt B, and Wekerle H. 1990. Immune function of the blood-brain barrier: incomplete presentation of protein (auto-)antigens by rat brain microvascular endothelium in vitro. *J Cell Biol* 110:1757-1766.
- Robichaud A, Stamatiou PB, Jin SL, Lachance N, Macdonald D, Laliberte F, Liu S, Huang Z, Conti M, and Chan CC. 2002. Deletion of phosphodiesterase 4D in mice shortens alpha(2)-adrenoceptor-mediated anesthesia, a behavioral correlate of emesis. *J Clin Invest* 110:1045-1052.
- Rocque WJ, Holmes WD, Patel IR, Dougherty RW, Ittoop O, Overton L, Hoffman CR, Wisely GB, Willard DH, and Luther MA. 1997. Detailed characterization of a purified type 4 phosphodiesterase, HSPDE4B2B: differentiation of high- and low-affinity (R)-rolipram binding. *Protein Expr Purif* 9:191-202.

- Rodefer JS, Murphy ER, and Baxter MG. 2005. PDE10A inhibition reverses subchronic PCP-induced deficits in attentional set-shifting in rats. *Eur J Neurosci* 21:1070-1076.
- Rogers J, Webster S, Lue LF, Brachova L, Civin WH, Emmerling M, Shivers B, Walker D, and McGeer P. 1996. Inflammation and Alzheimer's disease pathogenesis. *Neurobiol Aging* 17:681-686.
- Rohl C, Lucius R, and Sievers J. 2007. The effect of activated microglia on astrogliosis parameters in astrocyte cultures. *Brain Res* 1129:43-52.
- Ron D, Chen CH, Caldwell J, Jamieson L, Orr E, and Mochly-Rosen D. 1994. Cloning of an intracellular receptor for protein kinase C: a homolog of the beta subunit of G proteins. *Proc Natl Acad Sci U S A* 91:839-843.
- Rondinone CM, Carvalho E, Rahn T, Manganiello VC, Degerman E, and Smith UP. 2000. Phosphorylation of PDE3B by phosphatidylinositol 3-kinase associated with the insulin receptor. *J Biol Chem* 275:10093-10098.
- Rose GM, Hopper A, De Vivo M, and Tehim A. 2005. Phosphodiesterase inhibitors for cognitive enhancement. *Curr Pharm Des* 11:3329-3334.
- Rosen RC and Kostis JB. 2003. Overview of phosphodiesterase 5 inhibition in erectile dysfunction. *Am J Cardiol* 92:9M-18M.
- Rosi S, Ramirez-Amaya V, Vazdarjanova A, Worley PF, Barnes CA, and Wenk GL. 2005. Neuroinflammation alters the hippocampal pattern of behaviorally induced Arc expression. *J Neurosci* 25:723-731.
- Rosman GJ, Martins TJ, Sonnenburg WK, Beavo JA, Ferguson K, and Loughney K. 1997. Isolation and characterization of human cDNAs encoding a cGMP-stimulated 3',5'-cyclic nucleotide phosphodiesterase. *Gene* 191:89-95.
- Roth J, Harre EM, Rummel C, Gerstberger R, and Hubschle T. 2004. Signaling the brain in systemic inflammation: role of sensory circumventricular organs. *Front Biosci* 9:290-300.
- Rubin LL and Staddon JM. 1999. The cell biology of the blood-brain barrier. *Annu Rev Neurosci* 22:11-28.
- Rybalkin SD, Rybalkina IG, Shimizu-Albergine M, Tang XB, and Beavo JA. 2003. PDE5 is converted to an activated state upon cGMP binding to the GAF A domain. *EMBO J* 22:469-478.
- Sadhu K, Hensley K, Florio VA, and Wolda SL. 1999. Differential expression of the cyclic GMP-stimulated phosphodiesterase PDE2A in human venous and capillary endothelial cells. *J Histochem Cytochem* 47:895-906.
- Saeki T, Adachi H, Takase Y, Yoshitake S, Souda S, and Saito I. 1995. A selective type V phosphodiesterase inhibitor, E4021, dilates porcine large coronary artery. *J Pharmacol Exp Ther* 272:825-831.
- Sakaguchi T, Nakamura S, Suzuki S, Oda T, Ichiyama A, Baba S, and Okamoto T. 1999. Participation of platelet-activating factor in the lipopolysaccharide-induced liver injury in partially hepatectomized rats. *Hepatology* 30:959-967.
- Salanova M, Chun SY, Iona S, Puri C, Stefanini M, and Conti M. 1999. Type 4 cyclic adenosine monophosphate-specific phosphodiesterases are expressed in discrete subcellular compartments during rat spermiogenesis. *Endocrinology* 140:2297-2306.
- Sanchez AJ, Puerta C, Ballester S, Gonzalez P, Arriaga A, and Garcia-Merino A. 2005. Rolipram impairs NF-kappaB activity and MMP-9 expression in experimental autoimmune encephalomyelitis. *J Neuroimmunol* 168:13-20.
- Sandberg M, Natarajan V, Ronander I, Kalderon D, Walter U, Lohmann SM, and Jahnsen T. 1989. Molecular-Cloning and Predicted Full-Length Amino-Acid Sequence of the Type I-Beta-Isozyme of Cgmp-Dependent Protein-Kinase from Human-Placenta - Tissue Distribution and Developmental-Changes in Rat. *Febs Letters* 255:321-329.
- Sano R, Miki T, Suzuki Y, Shimada F, Taira M, Kanatsuka A, Makino H, Hashimoto N, and Saito Y. 2001. Analysis of the insulin-sensitive phosphodiesterase 3B gene in type 2 diabetes. *Diabetes Res Clin Pract* 54:79-88.
- Santambrogio L, Belyanskaya SL, Fischer FR, Cipriani B, Brosnan CF, Ricciardi-Castagnoli P, Stern LJ, Strominger JL, and Riese R. 2001. Developmental plasticity of CNS microglia. *Proc Natl Acad Sci U S A* 98:6295-6300.
- Sanz MJ, Cortijo J, and Morcillo EJ. 2005. PDE4 inhibitors as new anti-inflammatory drugs: effects on cell trafficking and cell adhesion molecules expression. *Pharmacol Ther* 106:269-297.
- Saper CB. 1998. Neurobiological basis of fever. *Ann N Y Acad Sci* 856:90-94.
- Sasaki T, Kotera J, and Omori K. 2002. Novel alternative splice variants of rat phosphodiesterase 7B showing unique tissue-specific expression and phosphorylation. *Biochem J* 361:211-220.
- Sasaki T, Kotera J, and Omori K. 2004. Transcriptional activation of phosphodiesterase 7B1 by dopamine D1 receptor stimulation through the cyclic AMP/cyclic AMP-dependent protein kinase/cyclic AMP-response element binding protein pathway in primary striatal neurons. *J Neurochem* 89:474-483.
- Sasaki T, Kotera J, Yuasa K, and Omori K. 2000. Identification of human PDE7B, a cAMP-specific phosphodiesterase. *Biochem Biophys Res Commun* 271:575-583.
- Scherbel U, Raghupathi R, Nakamura M, Saatman KE, Trojanowski JQ, Neugebauer E, Marino MW, and McIntosh TK. 1999. Differential acute and chronic responses of tumor necrosis factor-deficient mice to experimental brain injury. *Proceedings of the*

## Bibliografía

- National Academy of Sciences of the United States of America 96:8721-8726.
- Schiltz JC and Sawchenko PE. 2002. Distinct brain vascular cell types manifest inducible cyclooxygenase expression as a function of the strength and nature of immune insults. *J Neurosci* 22:5606-5618.
- Schmidt HH, Gagne GD, Nakane M, Pollock JS, Miller MF, and Murad F. 1992. Mapping of neural nitric oxide synthase in the rat suggests frequent co-localization with NADPH diaphorase but not with soluble guanylyl cyclase, and novel paraneural functions for nitrinergic signal transduction. *J Histochem Cytochem* 40:1439-1456.
- Schmidt K, Schrammel A, Koesling D, and Mayer B. 2001. Molecular mechanisms involved in the synergistic activation of soluble guanylyl cyclase by YC-1 and nitric oxide in endothelial cells. *Mol Pharmacol* 59:220-224.
- Schneider HH, Schmiechen R, Brezinski M, and Seidler J. 1986. Stereospecific binding of the antidepressant rolipram to brain protein structures. *Eur J Pharmacol* 127:105-115.
- Schnell L, Fearn S, Klassen H, Schwab ME, and Perry VH. 1999a. Acute inflammatory responses to mechanical lesions in the CNS: differences between brain and spinal cord. *Eur J Neurosci* 11:3648-3658.
- Schnell L, Fearn S, Schwab ME, Perry VH, and Anthony DC. 1999b. Cytokine-induced acute inflammation in the brain and spinal cord. *J Neuropathol Exp Neurol* 58:245-254.
- Schulz M and Engelhardt B. 2005. The circumventricular organs participate in the immunopathogenesis of experimental autoimmune encephalomyelitis. *Cerebrospinal Fluid Res* 2:8.
- Schulz S, Yuen PS, and Garbers DL. 1991. The expanding family of guanylyl cyclases. *Trends Pharmacol Sci* 12:116-120.
- Schwabe U, Miyake M, Ohga Y, and Daly JW. 1976. 4-(3-Cyclopentyloxy-4-methoxyphenyl)-2-pyrrolidone (ZK 62711): a potent inhibitor of adenosine cyclic 3',5'-monophosphate phosphodiesterases in homogenates and tissue slices from rat brain. *Mol Pharmacol* 12:900-910.
- Scotland G, Beard M, Erdogan S, Huston E, McCallum F, MacKenzie SJ, Peden AH, Pooley L, Rena NG, Ross AH, Yarwood SJ, and Houslay MD. 1998. Intracellular compartmentalization of PDE4 cyclic AMP-specific phosphodiesterases. *Methods* 14:65-79.
- Scott AI, Perini AF, Shering PA, and Whalley LJ. 1991. In-patient major depression: is rolipram as effective as amitriptyline? *Eur J Clin Pharmacol* 40:127-129.
- Scott JD. 1991. Cyclic nucleotide-dependent protein kinases. *Pharmacol Ther* 50:123-145.
- Scott PH and Lawrence JCJ. 1998. Attenuation of mammalian target of rapamycin activity by increased cAMP in 3T3-L1 adipocytes. *J Biol Chem* 273:34496-34501.
- Seeger TF, Bartlett B, Coskran TM, Culp JS, James LC, Krull DL, Lanfear J, Ryan AM, Schmidt CJ, Strick CA, Varghese AH, Williams RD, Wylie PG, and Menniti FS. 2003. Immunohistochemical localization of PDE10A in the rat brain. *Brain Res* 985:113-126.
- Seldon PM, Barnes PJ, Meja K, and Giembycz MA. 1995. Suppression of lipopolysaccharide-induced tumor necrosis factor- $\alpha$  generation from human peripheral blood monocytes by inhibitors of phosphodiesterase 4: interaction with stimulants of adenylyl cyclase. *Mol Pharmacol* 48:747-757.
- Selkoe DJ. 1991. The molecular pathology of Alzheimer's disease. *Neuron* 6:487-498.
- Selkoe DJ. 2004. Alzheimer disease: mechanistic understanding predicts novel therapies. *Ann Intern Med* 140:627-638.
- Sette C and Conti M. 1996. Phosphorylation and activation of a cAMP-specific phosphodiesterase by the cAMP-dependent protein kinase. Involvement of serine 54 in the enzyme activation. *J Biol Chem* 271:16526-16534.
- Sette C, Iona S, and Conti M. 1994. The short-term activation of a rolipram-sensitive, cAMP-specific phosphodiesterase by thyroid-stimulating hormone in thyroid FRTL-5 cells is mediated by a cAMP-dependent phosphorylation. *J Biol Chem* 269:9245-9252.
- Shabb JB, Ng L, and Corbin JD. 1990. One Amino-Acid Change Produces A High-Affinity Cgmp-Binding Site in Camp-Dependent Protein-Kinase. *Journal of Biological Chemistry* 265:16031-16034.
- Shakur Y, Pryde JG, and Houslay MD. 1993. Engineered deletion of the unique N-terminal domain of the cyclic AMP-specific phosphodiesterase RD1 prevents plasma membrane association and the attainment of enhanced thermostability without altering its sensitivity to inhibition by rolipram. *Biochem J* 292 ( Pt 3):677-686.
- Shaw JA, Perry VH, and Mellanby J. 1990. Tetanus toxin-induced seizures cause microglial activation in rat hippocampus. *Neurosci Lett* 120:66-69.
- Shepherd M, McSorley T, Olsen AE, Johnston LA, Thomson NC, Baillie GS, Houslay MD, and Bolger GB. 2003. Molecular cloning and subcellular distribution of the novel PDE4B4 cAMP-specific phosphodiesterase isoform. *Biochem J* 370:429-438.
- Shimizu-Albergine M, Rybalkin SD, Rybalkina IG, Feil R, Wolfsgruber W, Hofmann F, and Beavo JA. 2003. Individual cerebellar Purkinje cells express different cGMP phosphodiesterases (PDEs): in vivo phosphorylation of cGMP-specific PDE (PDE5) as an indicator of cGMP-dependent protein kinase (PKG) activation. *J Neurosci* 23:6452-6459.
- Shitsukawa K, Andersen CB, Richard FJ, Horner AK, Wiersma A, van Duin M, and Conti M. 2001. Cloning and characterization of the cyclic guanosine monophosphate-inhibited phosphodiesterase PDE3A expressed in mouse oocyte. *Biol Reprod* 65:188-196.

- Shrikant P and Benveniste EN. 1996. The central nervous system as an immunocompetent organ: role of glial cells in antigen presentation. *J Immunol* 157:1819-1822.
- Silva AJ. 2003. Molecular and cellular cognitive studies of the role of synaptic plasticity in memory. *J Neurobiol* 54:224-237.
- Silva AJ, Kogan JH, Frankland PW, and Kida S. 1998. CREB and memory. *Annu Rev Neurosci* 21:127-148.
- Simic G, Lucassen PJ, Krsnik Z, Kruslin B, Kostovic I, Winblad B, and Bogdanovic N. 2000. nNOS expression in reactive astrocytes correlates with increased cell death related DNA damage in the hippocampus and entorhinal cortex in Alzheimer's disease. *Experimental Neurology* 165:12-26.
- Simons K and Ikonen E. 1997. Functional rafts in cell membranes. *Nature* 387:569-572.
- Siuciak JA, McCarthy SA, Chapin DS, Fujiwara RA, James LC, Williams RD, Stock JL, McNeish JD, Strick CA, Menniti FS, and Schmidt CJ. 2006. Genetic deletion of the striatum-enriched phosphodiesterase PDE10A: Evidence for altered striatal function. *Neuropharmacology* 51:374-385.
- Skalhegg BS, Landmark BF, Doskeland SO, Hansson V, Lea T, and Jahnsen T. 1992. Cyclic AMP-dependent protein kinase type I mediates the inhibitory effects of 3',5'-cyclic adenosine monophosphate on cell replication in human T lymphocytes. *J Biol Chem* 267:15707-15714.
- Smith CJ, Huang R, Sun D, Ricketts S, Hoegler C, Ding JZ, Moggio RA, and Hintze TH. 1997. Development of decompensated dilated cardiomyopathy is associated with decreased gene expression and activity of the milrinone-sensitive cAMP phosphodiesterase PDE3A. *Circulation* 96:3116-3123.
- Smith KJ, Scotland G, Beattie J, Trayer IP, and Houslay MD. 1996. Determination of the structure of the N-terminal splice region of the cyclic AMP-specific phosphodiesterase RD1 (RNPDE4A1) by 1H NMR and identification of the membrane association domain using chimeric constructs. *J Biol Chem* 271:16703-16711.
- Smith SJ, Brookes-Fazakerley S, Donnelly LE, Barnes PJ, Barnette MS, and Giembycz MA. 2003. Ubiquitous expression of phosphodiesterase 7A in human proinflammatory and immune cells. *Am J Physiol Lung Cell Mol Physiol* 284:L279-L289.
- Smith SJ, Cieslinski LB, Newton R, Donnelly LE, Fenwick PS, Nicholson AG, Barnes PJ, Barnette MS, and Giembycz MA. 2004. Discovery of BRL 50481 [3-(N,N-dimethylsulfonamido)-4-methyl-nitrobenzene], a selective inhibitor of phosphodiesterase 7: in vitro studies in human monocytes, lung macrophages, and CD8+ T-lymphocytes. *Mol Pharmacol* 66:1679-1689.
- Sobel RA, Blanchette BW, Bhan AK, and Colvin RB. 1984. The immunopathology of experimental allergic encephalomyelitis. I. Quantitative analysis of inflammatory cells in situ. *J Immunol* 132:2393-2401.
- Soderling SH, Bayuga SJ, and Beavo JA. 1998a. Cloning and characterization of a cAMP-specific cyclic nucleotide phosphodiesterase. *Proc Natl Acad Sci U S A* 95:8991-8996.
- Soderling SH, Bayuga SJ, and Beavo JA. 1998b. Identification and characterization of a novel family of cyclic nucleotide phosphodiesterases. *J Biol Chem* 273:15553-15558.
- Soderling SH, Bayuga SJ, and Beavo JA. 1999. Isolation and characterization of a dual-substrate phosphodiesterase gene family: PDE10A. *Proc Natl Acad Sci U S A* 96:7071-7076.
- Soderling SH and Beavo JA. 2000. Regulation of cAMP and cGMP signaling: new phosphodiesterases and new functions. *Curr Opin Cell Biol* 12:174-179.
- Sommer N, Loschmann PA, Northoff GH, Weller M, Steinbrecher A, Steinbach JP, Lichtenfels R, Meyermann R, Riethmuller A, Fontana A, Dighgans J, Martin R, and . 1995. The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis. *Nat Med* 1:244-248.
- Sommer N, Martin R, McFarland HF, Quigley L, Cannella B, Raine CS, Scott DE, Loschmann PA, and Racke MK. 1997. Therapeutic potential of phosphodiesterase type 4 inhibition in chronic autoimmune demyelinating disease. *J Neuroimmunol* 79:54-61.
- Sospedra M and Martin R. 2005. Immunology of multiple sclerosis. *Annu Rev Immunol* 23:683-747.
- Souness JE, Aldous D, and Sargent C. 2000a. Immunosuppressive and anti-inflammatory effects of cyclic AMP phosphodiesterase (PDE) type 4 inhibitors. *Immunopharmacology* 47:127-162.
- Souness JE, Aldous D, and Sargent C. 2000b. Immunosuppressive and anti-inflammatory effects of cyclic AMP phosphodiesterase (PDE) type 4 inhibitors. *Immunopharmacology* 47:127-162.
- Souness JE and Rao S. 1997. Proposal for pharmacologically distinct conformers of PDE4 cyclic AMP phosphodiesterases. *Cell Signal* 9:227-236.
- Southam E and Garthwaite J. 1993. The nitric oxide-cyclic GMP signalling pathway in rat brain. *Neuropharmacology* 32:1267-1277.
- Spina D. 2003. Phosphodiesterase-4 inhibitors in the treatment of inflammatory lung disease. *Drugs* 63:2575-2594.
- Springer TA. 1994. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. *Cell* 76:301-314.
- Stacey P, Rulten S, Dapling A, and Phillips SC. 1998. Molecular cloning and expression of human cGMP-binding cGMP-specific phosphodiesterase (PDE5). *Biochem Biophys Res Commun* 247:249-254.
- Stasch JP, Becker EM, Alonso-Alija C, Apeler H, Dembowsky K, Feurer A, Gerzer R, Minuth T, Perzborn E, Pleiss U, Schroder H, Schroeder

## Bibliografía

- W, Stahl E, Steinke W, Straub A, and Schramm M. 2001. NO-independent regulatory site on soluble guanylate cyclase. *Nature* 410:212-215.
- Steele MR, McCahill A, Thompson DS, MacKenzie C, Isaacs NW, Houslay MD, and Bolger GB. 2001. Identification of a surface on the beta-propeller protein RACK1 that interacts with the cAMP-specific phosphodiesterase PDE4D5. *Cell Signal* 13:507-513.
- Stein CA. 2001. The experimental use of antisense oligonucleotides: a guide for the perplexed. *Journal of Clinical Investigation* 108:641-644.
- Steiner AA, Ivanov AI, Serrats J, Hosokawa H, Phayre AN, Robbins JR, Roberts JL, Kobayashi S, Matsumura K, Sawchenko PE, and Romanovsky AA. 2006. Cellular and molecular bases of the initiation of Fever. *PLoS Biol* 4:e284.
- Steiner MK, Preston IR, Klinger JR, and Hill NS. 2005. Pulmonary hypertension: inhaled nitric oxide, sildenafil and natriuretic peptides. *Curr Opin Pharmacol* 5:245-250.
- Steinman L. 1993. Autoimmune disease. *Sci Am* 269:106-114.
- Steinman L and Zamvil SS. 2006. How to successfully apply animal studies in experimental allergic encephalomyelitis to research on multiple sclerosis. *Annals of Neurology* 60:12-21.
- Stern EL, Quan N, Proescholdt MG, and Herkenham M. 2000. Spatiotemporal induction patterns of cytokine and related immune signal molecule mRNAs in response to intrastriatal injection of lipopolysaccharide. *J Neuroimmunol* 109:245-260.
- Streit WJ. 2004. Microglia and Alzheimer's disease pathogenesis. *J Neurosci Res* 77:1-8.
- Streit WJ and Kincaid-Colton CA. 1995. The brain's immune system. *Sci Am* 273:54-61.
- Stryer L. 1996. Vision: from photon to perception. *Proc Natl Acad Sci U S A* 93:557-559.
- Sudo T, Tachibana K, Toga K, Tochizawa S, Inoue Y, Kimura Y, and Hidaka H. 2000. Potent effects of novel anti-platelet aggregatory cilostamide analogues on recombinant cyclic nucleotide phosphodiesterase isozyme activity. *Biochem Pharmacol* 59:347-356.
- Sullivan M, Olsen AS, and Houslay MD. 1999. Genomic organisation of the human cyclic AMP-specific phosphodiesterase PDE4C gene and its chromosomal localisation to 19p13.1, between RAB3A and JUND. *Cell Signal* 11:735-742.
- Sullivan M, Rena G, Begg F, Gordon L, Olsen AS, and Houslay MD. 1998. Identification and characterization of the human homologue of the short PDE4A cAMP-specific phosphodiesterase RD1 (PDE4A1) by analysis of the human HSPDE4A gene locus located at chromosome 19p13.2. *Biochem J* 333 ( Pt 3):693-703.
- Sunahara RK, Dessauer CW, and Gilman AG. 1996. Complexity and diversity of mammalian adenylyl cyclases. *Annu Rev Pharmacol Toxicol* 36:461-480.
- Sundkvist E, Jaeger R, and Sager G. 2002. Pharmacological characterization of the ATP-dependent low K-m guanosine 3',5'-cyclic monophosphate (cGMP) transporter in human erythrocytes. *Biochemical Pharmacology* 63:945-949.
- Sung BJ, Hwang KY, Jeon YH, Lee JI, Heo YS, Kim JH, Moon J, Yoon JM, Hyun YL, Kim E, Eum SJ, Park SY, Lee JO, Lee TG, Ro S, and Cho JM. 2003. Structure of the catalytic domain of human phosphodiesterase 5 with bound drug molecules. *Nature* 425:98-102.
- Sutherland EW and Rall TW. 1958. Fractionation and characterization of a cyclic adenine ribonucleotide formed by tissue particles. *J Biol Chem* 232:1077-1091.
- Suttorp N, Ehreiser P, Hippenstiel S, Fuhrmann M, Krull M, Tenor H, and Schudt C. 1996a. Hyperpermeability of pulmonary endothelial monolayer: Protective role of phosphodiesterase isoenzymes 3 and 4. *Lung* 174:181-194.
- Suttorp N, Hippenstiel S, Fuhrmann M, Krull M, and Podzuweit T. 1996b. Role of nitric oxide and phosphodiesterase isoenzyme II for reduction of endothelial hyperpermeability. *American Journal of Physiology-Cell Physiology* 39:C778-C785.
- Suttorp N, Weber U, Welsch T, and Schudt C. 1993. Role of phosphodiesterases in the regulation of endothelial permeability in vitro. *J Clin Invest* 91:1421-1428.
- Swinnen JV, Joseph DR, and Conti M. 1989a. Molecular cloning of rat homologues of the *Drosophila melanogaster dunce* cAMP phosphodiesterase: evidence for a family of genes. *Proc Natl Acad Sci U S A* 86:5325-5329.
- Swinnen JV, Joseph DR, and Conti M. 1989b. The mRNA encoding a high-affinity cAMP phosphodiesterase is regulated by hormones and cAMP. *Proc Natl Acad Sci U S A* 86:8197-8201.
- Szabo C. 1996. Physiological and pathophysiological roles of nitric oxide in the central nervous system. *Brain Res Bull* 41:131-141.
- Szpirer C, Szpirer J, Riviere M, Swinnen J, Vicini E, and Conti M. 1995. Chromosomal localization of the human and rat genes (PDE4D and PDE4B) encoding the cAMP-specific phosphodiesterases 3 and 4. *Cytogenet Cell Genet* 69:11-14.
- Takahashi M, Terwilliger R, Lane C, Mezes PS, Conti M, and Duman RS. 1999. Chronic antidepressant administration increases the expression of cAMP-specific phosphodiesterase 4A and 4B isoforms. *J Neurosci* 19:610-618.
- Takahashi M and Tokuyama S. 1998. Pharmacological and physiological effects of ginseng on actions induced by opioids and psychostimulants. *Methods Find Exp Clin Pharmacol* 20:77-84.

- Takahashi N, Tetsuka T, Uranishi H, and Okamoto T. 2002. Inhibition of the NF-kappaB transcriptional activity by protein kinase A. *Eur J Biochem* 269:4559-4565.
- Takimoto E, Champion HC, Belardi D, Moslehi J, Mongillo M, Mergia E, Montrose DC, Isoda T, Auffero K, Zaccolo M, Dostmann WR, Smith CJ, and Kass DA. 2005. cGMP catabolism by phosphodiesterase 5A regulates cardiac adrenergic stimulation by NOS3-dependent mechanism. *Circulation Research* 96:100-109.
- Takuma K, Phuagphong P, Lee E, Mori K, Baba A, and Matsuda T. 2001. Anti-apoptotic effect of cGMP in cultured astrocytes: inhibition by cGMP-dependent protein kinase of mitochondrial permeable transition pore. *J Biol Chem* 276:48093-48099.
- Tang Y, Osawa H, Onuma H, Nishimiya T, Ochi M, Sugita A, and Makino H. 2001. Phosphodiesterase 3B gene expression is enhanced in the liver but reduced in the adipose tissue of obese insulin resistant db/db mouse. *Diabetes Res Clin Pract* 54:145-155.
- Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, and Gergel I. 2004. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. *JAMA* 291:317-324.
- Tasken K and Aandahl EM. 2004. Localized effects of cAMP mediated by distinct routes of protein kinase A. *Physiol Rev* 84:137-167.
- Tasken K and Stokka AJ. 2006. The molecular machinery for cAMP-dependent immunomodulation in T-cells. *Biochem Soc Trans* 34:476-479.
- Tasken KA, Collas P, Kemmner WA, Witczak O, Conti M, and Tasken K. 2001. Phosphodiesterase 4D and protein kinase a type II constitute a signaling unit in the centrosomal area. *J Biol Chem* 276:21999-22002.
- Tcheudji JFK, Lebeau L, Virmaux N, Maffei CG, Cote RH, Lugnier C, and Schultz P. 2001. Molecular organization of bovine rod cGMP-phosphodiesterase 6. *Journal of Molecular Biology* 310:781-791.
- Teixeira MM, Gristwood RW, Cooper N, and Hellewell PG. 1997. Phosphodiesterase (PDE)4 inhibitors: anti-inflammatory drugs of the future? *Trends Pharmacol Sci* 18:164-171.
- Terayama R, Bando Y, Yamada M, and Yoshida S. 2005. Involvement of neuropsin in the pathogenesis of experimental autoimmune encephalomyelitis. *Glia* 52:108-118.
- Terry R, Cheung YF, Praestegaard M, Baillie GS, Huston E, Gall I, Adams DR, and Houslay MD. 2003. Occupancy of the catalytic site of the PDE4A4 cyclic AMP phosphodiesterase by rolipram triggers the dynamic redistribution of this specific isoform in living cells through a cyclic AMP independent process. *Cell Signal* 15:955-971.
- Thomas MK, Francis SH, and Corbin JD. 1990. Substrate-Directed and Kinase-Directed Regulation of Phosphorylation of A Cgmp-Binding Phosphodiesterase by Cgmp. *Journal of Biological Chemistry* 265:14971-14978.
- Thomas WE. 1992. Brain macrophages: evaluation of microglia and their functions. *Brain Res Brain Res Rev* 17:61-74.
- Thomas WE. 1999. Brain macrophages: on the role of pericytes and perivascular cells. *Brain Res Brain Res Rev* 31:42-57.
- Thompson WJ and Appleman MM. 1971. Multiple cyclic nucleotide phosphodiesterase activities from rat brain. *Biochemistry* 10:311-316.
- Torrás-Llort M and Azorin F. 2003. Functional characterization of the human phosphodiesterase 7A1 promoter. *Biochem J* 373:835-843.
- Tremblay J, Desjardins R, Hum D, Gutkowska J, and Hamet P. 2002. Biochemistry and physiology of the natriuretic peptide receptor guanylyl cyclases. *Molecular and Cellular Biochemistry* 230:31-47.
- Tully T, Bourtchouladze R, Scott R, and Tallman J. 2003. Targeting the CREB pathway for memory enhancers. *Nat Rev Drug Discov* 2:267-277.
- Tuohy VK, Lu Z, Sobel RA, Laursen RA, and Lees MB. 1989. Identification of an encephalitogenic determinant of myelin proteolipid protein for SJL mice. *J Immunol* 142:1523-1527.
- Turowski P, Adamson P, and Greenwood J. 2005. Pharmacological targeting of ICAM-1 signaling in brain endothelial cells: potential for treating neuroinflammation. *Cell Mol Neurobiol* 25:153-170.
- Turrin NP, Gayle D, Ilyin SE, Flynn MC, Langhans W, Schwartz GJ, and Plata-Salaman CR. 2001. Pro-inflammatory and anti-inflammatory cytokine mRNA induction in the periphery and brain following intraperitoneal administration of bacterial lipopolysaccharide. *Brain Res Bull* 54:443-453.
- Ubogu EE, Cossoy MB, and Ransohoff RM. 2006. The expression and function of chemokines involved in CNS inflammation. *Trends Pharmacol Sci* 27:48-55.
- Ueda N, Iniguez-Lluhi JA, Lee E, Smrcka AV, Robishaw JD, and Gilman AG. 1994. G protein beta gamma subunits. Simplified purification and properties of novel isoforms. *J Biol Chem* 269:4388-4395.
- Ulvestad E, Williams K, Bjerkvig R, Tiekotter K, Antel J, and Matre R. 1994. Human microglial cells have phenotypic and functional characteristics in common with both macrophages and dendritic antigen-presenting cells. *J Leukoc Biol* 56:732-740.
- Vallar L, Spada A, and Giannattasio G. 1987. Altered Gs and Adenylate-Cyclase Activity in Human Gh-Secreting Pituitary-Adenomas. *Nature* 330:566-569.
- van Staveren WC, Glick J, Markerink-Van Ittersum M, Shimizu M, Beavo JA, Steinbusch HW, and de Vente J. 2002. Cloning and localization of the cGMP-specific phosphodiesterase type 9 in the rat brain. *J Neurocytol* 31:729-741.
- van Staveren WC, Steinbusch HW, Markerink-Van Ittersum M, Repaske DR, Goy MF, Kotera J,

## Bibliografía

- Omori K, Beavo JA, and de Vente J. 2003. mRNA expression patterns of the cGMP-hydrolyzing phosphodiesterases types 2, 5, and 9 during development of the rat brain. *J Comp Neurol* 467:566-580.
- Vasta V, Shimizu-Albergine M, and Beavo JA. 2006. Modulation of Leydig cell function by cyclic nucleotide phosphodiesterase 8A. *Proc Natl Acad Sci U S A* 103:19925-19930.
- Verde I, Pahlke G, Salanova M, Zhang G, Wang S, Coletti D, Onuffer J, Jin SL, and Conti M. 2001. Myomegalin is a novel protein of the golgi/centrosome that interacts with a cyclic nucleotide phosphodiesterase. *J Biol Chem* 276:11189-11198.
- Vicini E and Conti M. 1997. Characterization of an intronic promoter of a cyclic adenosine 3',5'-monophosphate (cAMP)-specific phosphodiesterase gene that confers hormone and cAMP inducibility. *Mol Endocrinol* 11:839-850.
- Vignola AM. 2004. PDE4 inhibitors in COPD--a more selective approach to treatment. *Respir Med* 98:495-503.
- Vilaró MT, Wiederhold KH, Palacios JM, and Mengod G. 1992. Muscarinic M2-selective ligands also recognize M4 receptors in the rat brain: evidence from combined in situ hybridization and receptor autoradiography. *Synapse* 11:171-183.
- Villoslada P, Hauser SL, Bartke I, Unger J, Heald N, Rosenberg D, Cheung SW, Mobley WC, Fisher S, and Genain CP. 2000. Human nerve growth factor protects common marmosets against autoimmune encephalomyelitis by switching the balance of T helper cell type 1 and 2 cytokines within the central nervous system. *Journal of Experimental Medicine* 191:1799-1806.
- Vitolo OV, Sant'Angelo A, Costanzo V, Battaglia F, Arancio O, and Shelanski M. 2002. Amyloid beta -peptide inhibition of the PKA/CREB pathway and long-term potentiation: Reversibility by drugs that enhance cAMP signaling. *Proc Natl Acad Sci U S A* 99:13217-13221.
- Wachtel H. 1983. Potential antidepressant activity of rolipram and other selective cyclic adenosine 3',5'-monophosphate phosphodiesterase inhibitors. *Neuropharmacology* 22:267-272.
- Walsh DA, Perkins JP, and Krebs EG. 1968. An adenosine 3',5'-monophosphate-dependant protein kinase from rabbit skeletal muscle. *J Biol Chem* 243:3763-3765.
- Wang H, Lee Y, and Malbon CC. 2004. PDE6 is an effector for the Wnt/Ca2+/cGMP-signalling pathway in development. *Biochem Soc Trans* 32:792-796.
- Wang P, Wu P, Egan RW, and Billah MM. 2001. Human phosphodiesterase 8A splice variants: cloning, gene organization, and tissue distribution. *Gene* 280:183-194.
- Wang P, Wu P, Egan RW, and Billah MM. 2003. Identification and characterization of a new human type 9 cGMP-specific phosphodiesterase splice variant (PDE9A5). Differential tissue distribution and subcellular localization of PDE9A variants. *Gene* 314:15-27.
- Wang P, Wu P, Ohleth KM, Egan RW, and Billah MM. 1999. Phosphodiesterase 4B2 is the predominant phosphodiesterase species and undergoes differential regulation of gene expression in human monocytes and neutrophils. *Mol Pharmacol* 56:170-174.
- Wayman C, Phillips S, Lunny C, Webb T, Fawcett L, Baxendale R, and Burgess G. 2005. Phosphodiesterase 11 (PDE11) regulation of spermatozoa physiology. *Int J Impot Res* 17:216-223.
- Weber IT, Shabb JB, and Corbin JD. 1989. Predicted Structures of the Cgmp Binding Domains of the Cgmp-Dependent Protein-Kinase - A Key Alanine Threonine Difference in Evolutionary Divergence of Camp and Cgmp Binding-Sites. *Biochemistry* 28:6122-6127.
- Wedel BJ and Garbers DL. 2001. The guanylyl cyclase family at Y2K. *Annual Review of Physiology* 63:215-233.
- Weeks JL, Zoraghi R, Beasley A, Sekhar KR, Francis SH, and Corbin JD. 2005. High biochemical selectivity of tadalafil, sildenafil and vardenafil for human phosphodiesterase 5A1 (PDE5) over PDE11A4 suggests the absence of PDE11A4 cross-reaction in patients. *Int J Impot Res* 17:5-9.
- Wei JY, Roy DS, Leconte L, and Barnstable CJ. 1998. Molecular and pharmacological analysis of cyclic nucleotide-gated channel function in the central nervous system. *Progress in Neurobiology* 56:37-64.
- Weiner HL and Frenkel D. 2006. Immunology and immunotherapy of Alzheimer's disease. *Nature Reviews Immunology* 6:404-416.
- Wernet W and Flockerzi V. 1989. Primary Structure of Mammalian Cgmp-Dependent Protein-Kinase. *Biological Chemistry Hoppe-Seyler* 370:788.
- Wilkie TM, Gilbert DJ, Olsen AS, Chen XN, Amatruda TT, Korenberg JR, Trask BJ, de Jong P, Reed RR, Simon MI, and . 1992. Evolution of the mammalian G protein alpha subunit multigene family. *Nat Genet* 1:85-91.
- Wilson M, Sullivan M, Brown N, and Houslay MD. 1994. Purification, characterization and analysis of rolipram inhibition of a human type-IVA cyclic AMP-specific phosphodiesterase expressed in yeast. *Biochem J* 304 ( Pt 2):407-415.
- Wolfe L, Corbin JD, and Francis SH. 1989. Characterization of A Novel Isozyme of Cgmp-Dependent Protein-Kinase from Bovine Aorta. *Journal of Biological Chemistry* 264:7734-7741.
- Wong D, Prameya R, and Dorovini-Zis K. 1999. In vitro adhesion and migration of T lymphocytes across monolayers of human brain microvessel endothelial cells: regulation by ICAM-1, VCAM-1, E-selectin and PECAM-1. *J Neuropathol Exp Neurol* 58:138-152.

- Wunder F, Tersteegen A, Rebmann A, Erb C, Fahrig T, and Hendrix M. 2005. Characterization of the first potent and selective PDE9 inhibitor using a cGMP reporter cell line. *Mol Pharmacol* 68:1775-1781.
- Xie Z, Adamowicz WO, Eldred WD, Jakowski AB, Kleiman RJ, Morton DG, Stephenson DT, Strick CA, Williams RD, and Menniti FS. 2006. Cellular and subcellular localization of PDE10A, a striatum-enriched phosphodiesterase. *Neuroscience* 139:597-607.
- Xu RX, Hassell AM, Vanderwall D, Lambert MH, Holmes WD, Luther MA, Rocque WJ, Milburn MV, Zhao Y, Ke H, and Nolte RT. 2000. Atomic structure of PDE4: insights into phosphodiesterase mechanism and specificity. *Science* 288:1822-1825.
- Yamagata K, Matsumura K, Inoue W, Shiraki T, Suzuki K, Yasuda S, Sugiura H, Cao C, Watanabe Y, and Kobayashi S. 2001. Coexpression of microsomal-type prostaglandin synthase with cyclooxygenase-2 in brain endothelial cells of rats during endotoxin-induced fever. *J Neurosci* 21:2669-2677.
- Yamashita N, Hayashi A, Baba J, and Sawa A. 1997. Rolipram, a phosphodiesterase-4-selective inhibitor, promotes the survival of cultured rat dopaminergic neurons. *Jpn J Pharmacol* 75:155-159.
- Yan C, Bentley JK, Sonnenburg WK, and Beavo JA. 1994. Differential expression of the 61 kDa and 63 kDa calmodulin-dependent phosphodiesterases in the mouse brain. *J Neurosci* 14:973-984.
- Yan C, Zhao AZ, Bentley JK, and Beavo JA. 1996. The calmodulin-dependent phosphodiesterase gene PDE1C encodes several functionally different splice variants in a tissue-specific manner. *Journal of Biological Chemistry* 271:25699-25706.
- Yanaka N, Kotera J, Ohtsuka A, Akatsuka H, Imai Y, Michibata H, Fujishige K, Kawai E, Takebayashi S, Okumura K, and Omori K. 1998. Expression, structure and chromosomal localization of the human cGMP-binding cGMP-specific phosphodiesterase PDE5A gene. *Eur J Biochem* 255:391-399.
- Yang G and Li L. 2003. In vivo effects of phosphodiesterase III inhibitors on glucose metabolism and insulin sensitivity. *J Chin Med Assoc* 66:210-216.
- Yang G, McIntyre KW, Townsend RM, Shen HH, Pitts WJ, Dodd JH, Nadler SG, McKinnon M, and Watson AJ. 2003. Phosphodiesterase 7A-deficient mice have functional T cells. *J Immunol* 171:6414-6420.
- Yang Q, Paskind M, Bolger G, Thompson WJ, Repaske DR, Cutler LS, and Epstein PM. 1994. A novel cyclic GMP stimulated phosphodiesterase from rat brain. *Biochem Biophys Res Commun* 205:1850-1858.
- Yarwood SJ, Sale EM, Sale GJ, Houslay MD, Kilgour E, and Anderson NG. 1999a. Growth hormone-dependent differentiation of 3T3-F442A preadipocytes requires Janus kinase/signal transducer and activator of transcription but not mitogen-activated protein kinase or p70 S6 kinase signaling. *J Biol Chem* 274:8662-8668.
- Yarwood SJ, Steele MR, Scotland G, Houslay MD, and Bolger GB. 1999b. The RACK1 signaling scaffold protein selectively interacts with the cAMP-specific phosphodiesterase PDE4D5 isoform. *J Biol Chem* 274:14909-14917.
- Yermakova A and O'Banion MK. 2000. Cyclooxygenases in the central nervous system: implications for treatment of neurological disorders. *Curr Pharm Des* 6:1755-1776.
- Yoshimura M and Tabakoff B. 1999. Ethanol's actions on cAMP-mediated signaling in cells transfected with type VII adenylyl cyclase. *Alcoholism-Clinical and Experimental Research* 23:1457-1461.
- Yuasa K, Kanoh Y, Okumura K, and Omori K. 2001a. Genomic organization of the human phosphodiesterase PDE11A gene. Evolutionary relatedness with other PDEs containing GAF domains. *Eur J Biochem* 268:168-178.
- Yuasa K, Kotera J, Fujishige K, Michibata H, Sasaki T, and Omori K. 2000. Isolation and characterization of two novel phosphodiesterase PDE11A variants showing unique structure and tissue-specific expression. *J Biol Chem* 275:31469-31479.
- Yuasa K, Ohgaru T, Asahina M, and Omori K. 2001b. Identification of rat cyclic nucleotide phosphodiesterase 11A (PDE11A): comparison of rat and human PDE11A splicing variants. *Eur J Biochem* 268:4440-4448.
- Zeller E, Stief HJ, Pflug B, and Sastre. 1984. Results of a phase II study of the antidepressant effect of rolipram. *Pharmacopsychiatry* 17:188-190.
- Zgaljardic DJ, Borod JC, Foldi NS, and Mattis P. 2003. A review of the cognitive and behavioral sequelae of Parkinson's disease: relationship to frontostriatal circuitry. *Cogn Behav Neurol* 16:193-210.
- Zhang B, Yang L, Konishi Y, Maeda N, Sakanaka M, and Tanaka J. 2002a. Suppressive effects of phosphodiesterase type IV inhibitors on rat cultured microglial cells: comparison with other types of cAMP-elevating agents. *Neuropharmacology* 42:262-269.
- Zhang H, Huang Y, Jin S, Frith S, Suvarna N, Conti M, and O'Donnell J. 2002b. Antidepressant-like Profile and Reduced Sensitivity to Rolipram in Mice Deficient in the PDE4D Phosphodiesterase Enzyme. *Neuropsychopharmacology* 27:587.
- Zhang J and Snyder SH. 1995. Nitric-Oxide in the Nervous-System. *Annual Review of Pharmacology and Toxicology* 35:213-233.
- Zhang Y, Han HY, Elmquist WF, and Miller DW. 2000a. Expression of various multidrug resistance-associated protein (MRP)



## *Bibliografía*

---

- homologues in brain microvessel endothelial cells. *Brain Research* 876:148-153.
- Zhang YH, Lu J, Elmquist JK, and Saper CB. 2000b. Lipopolysaccharide activates specific populations of hypothalamic and brainstem neurons that project to the spinal cord. *J Neurosci* 20:6578-6586.
- Zhang YH, Lu J, Elmquist JK, and Saper CB. 2003. Specific roles of cyclooxygenase-1 and cyclooxygenase-2 in lipopolysaccharide-induced fever and Fos expression in rat brain. *J Comp Neurol* 463:3-12.
- Zhao AZ, Yan C, Sonnenburg WK, and Beavo JA. 1997. Recent advances in the study of Ca<sup>2+</sup>/CaM-activated phosphodiesterases: expression and physiological functions. *Adv Second Messenger Phosphoprotein Res* 31:237-251.
- Zhong Y and Wu CF. 1991. Altered synaptic plasticity in *Drosophila* memory mutants with a defective cyclic AMP cascade. *Science* 251:198-201.
- Zoraghi R, Bessay EP, Corbin JD, and Francis SH. 2005. Structural and functional features in human PDE5A1 regulatory domain that provide for allosteric cGMP binding, dimerization, and regulation. *J Biol Chem* 280:12051-12063.
- Zufall F, Firestein S, and Shepherd GM. 1994. Cyclic Nucleotide-Gated Ion Channels and Sensory Transduction in Olfactory Receptor Neurons. *Annual Review of Biophysics and Biomolecular Structure* 23:577-607.
- Zufall F, Shepherd GM, and Barnstable CJ. 1997. Cyclic nucleotide gated channels as regulators of CNS development and plasticity. *Current Opinion in Neurobiology* 7:404-412.